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      New methodologies to target and deliver osteogenic factors offer significant potential 
for craniofacial tissue engineering. LIM domain mineralization protein (LMP) appears to 
be such a candidate for periodontal bone regeneration. The main purpose of this 
dissertation was to explore the function and regulation of LMP1 in periodontium, 
specifically in periodontal ligament (PDL) cell, and to evaluate the potential of LMP gene 
therapy in promoting periodontal bone formation. Using laser capture microdissection, 
LMP1 was found to be highly expressed in PDL and gingival tissue, and at lower level in 
mature alveolar bone. During tooth extraction socket healing, LMP1 expression modestly 
increased over time. However, in the healing of osteotomy defects around implants, 
LMP1 expression was gradually decreased. In experimental periodontitis model, LMP1 
gene expression was upregulated in the inflamed gingival tissue. The physiological 
function of LMP1 was also investigated by a loss-of-function strategy. Stable knockdown 
of LMP1 in PDL cell resulted in impaired cell proliferation and subsequent delay in 
mineralization. Adenoviral gene delivery of LMP1 and LMP3 (a truncated transcription 
variant without any LIM domain) was performed to assess the potential of LMP gene 
transduction in enhancing bone formation. AdLMP3 but not AdLMP1 significantly 
induced matrix mineralization in PDL cell and bone marrow stromal cell in vitro. 
However, AdLMP3 transduced-PDL cells failed to induce ectopic bone formation in 
xiv 
 
immunocompromised animals. Interestingly, AdLMP1 and AdBMP7 combinatory gene 
therapy led to increased bone formation above that of AdBMP7 treatment alone. More 
studies are needed to understand the mechanisms underlying this synergistic effect. The 
regulatory mechanism of LMP1 gene expression was identified in this thesis as well. 
LMP1 gene expression is regulated by TGF-β1 in PDL cell and other preosteoblast. 
TAK1-JNK/p38 kinase cascade was involved in this regulation event. Gene knockdown 
LMP1 affected the TGF-β1 effect on PDL proliferation. In summary, this dissertation 
established the gene expression profiles of LMP1 in normal, diseased, and regenerating 
periodontium, determined the function of LMP1 on PDL cell proliferation and 
differentiation, investigated the potential of LMP gene therapy in periodontal 















1.1 Periodontal disease 
Periodontal diseases are characterized by an inflammatory reaction of periodontal 
tissue in response to bacterial biofilms that accumulated on tooth root surfaces.  This 
leads to destruction of tooth-supporting tissue, including alveolar bone, tooth root 
cementum, and periodontal ligament [1]. This disease is one of the most common oral 
inflammatory infectious diseases, of which 31% of the United State population exhibit 
mild forms, 13% display moderate forms, and 4% have advanced disease symptoms [2]. 
Periodontal disease is the leading cause of tooth loss in adult and it has also been 
associated with systemic diseases such as atherosclerosis, heart failure, and diabetes [1]. 
 
Lipolysaccharides (LPS), a major component of the outer membrane of Gram-
negative bacteria, initiates the cascade of events leading to periodontal tissue destruction 
[1]. To describe this process briefly, LPS derived from periodontal biofilms on the tooth 
surface triggers the recruitment of polymorphonuclear leukocytes (PMN) to the site, 
followed by monocytes and activated macrophages. This inflammatory infiltration from 
the gingival tissue produces various inflammatory molecules, such as matrix 
metalloproteinases (MMPs), pro-inflammatory cytokines, and prostaglandins. Proteases 
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degrade the collagen structure of periodontal tissues and thus lead to further leukocyte 
infiltration. Interleukin (IL)-1β, tumor necrosis factor-α (TNF-α) and receptor activator of 
nuclear factor-kappa B ligand (RANKL) are elevated in active sites and mediate 
osteoclastogensis and bone breakdown [1, 3].  
 
Currently, various therapies have been developed to regenerate the lost periodontium, 
such as guided tissue regeneration (GTR), osseous grafting and application of 
recombinant growth factors. However, complete and predictable regeneration is still a 
considerable challenge in periodontology, especially in advanced periodontal diseases, 
due to the complex microenvironment of the periodontal wound.  The following factors 
contribute to the problems in regeneration: 1) Periodontal wounds are contaminated with 
tooth-associated biofilms of the anaerobic bacteria; compounding this, the transmucosal 
hard-soft tissue environment allows entry of pathogens into wounds. 2) Multiple 
junctional complex and stromal-cellular interactions create difficulty in rebuilding tissue 
interfaces (e.g., tooth-PDL-bone and epithelium-connective tissue-bone). 3) The effects 
of occlusal forces deliver intermittent loads in axial and transverse dimensions. 4) 
Limited blood supply in the cementum [4-6].  
 
1.2 Periodontal tissue engineering 
Tissue engineering is an interdisciplinary field that applies the principles of 
engineering and the life sciences toward the development of biological substitutes that 
restore, maintain, or improve tissue function [7]. Recently, the concept of tissue 
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engineering has been applied in periodontal regeneration. The factors critical to the 
outcome of periodontal tissue engineering have been expanded in the last couple of years 
[8]. To date, it is believed that the following six aspects should, at least, be considered for 
successful periodontal regeneration: appropriate cells, signals, blood supply, scaffold, 
mechanical loading, and pathogen control (Figure 1-1). Cells provide the machinery for 
new tissue growth and differentiation. Growth factors or morphogens modulate the 
cellular activity and provide stimuli to cells to differentiate and produce matrix toward 
the developing tissue. A three-dimensional template structure is provided by scaffolds to 
facilitate the above processes critical for tissue regeneration [8]. New vascular networks 
promoted by angiogenic signals provide the nutritional base for tissue growth and 
homeostasis, while appropriate mechanical loading would be essential for the 
development of highly organized, functional periodontal ligament fibers. Finally, because 
of the microbial bath in the periodontal sites, strategies in controlling infection are 
required to optimize periodontal regeneration. 
 
This paper will review current advancements in tissue engineering concerning the 
areas of periodontal inflammation prevention and treatment. Development of scaffolds 
designed for periodontal tissue engineering will be discussed and potential cell sources 
for future clinical periodontal regeneration will be summarized. A review of different 
gene delivery methods (non-viral and viral) and target genes to promote periodontal soft 
and hard tissue regeneration will be highlighted, followed by recent attempts in genetic 




1.3  Cells involved in periodontal regeneration  
Cells are the center of new tissue growth and differentiation. In cell-based 
regenerative medicine, cells are delivered to a donor with the goal of improving the 
regeneration process. Initial reports in the 1970s by WT Green, a pediatric orthopedic 
surgeon, demonstrated that implanted spicules and cartilage seeded with chondrocytes 
into animals could generate new cartilage [9]. Researchers delivered cells to accelerate 
periodontal regeneration for two purposes: 1) using cells as carriers to deliver growth 
factors, and 2) providing seed cells which are able to differentiate to multiple cell types in 
periodontium to promote regeneration. In the first, use of cells as carriers to deliver 
growth factors can stimulate an endogenous regeneration process. This strategy has been 
intensively investigated in both soft and hard tissue regeneration in oral and periodontal 
tissues, and some products in this area are being tested in clinical trials. Although 
periodontal regeneration can be seen in physiological status or wounding healing, the 
level and scale of this regeneration are very limited due to several reasons, one of which 
is lack of stem cells. With the development of stem cell research in the last several years, 
various stem cell types have been evaluated for their potential in periodontal regeneration 
[10].  
Mesenchymal stem cells (MSCs) are self-renewable and can differentiate into a 
variety of cell types that form mesenchymal and connective tissues [11, 12]. Bone 
marrow stromal cells are the most widely investigated MSCs because they are easily 
accessible. Bone marrow stromal cells were first isolated in the 1960s based on their 
unique ability to adhere to the plastic substrate of cell culture plates [13]. Since then, this 
simple protocol has been widely used to isolate MSC from many tissues such as adipose 
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tissue, muscle, liver, pancreas, and cartilage. MSCs have great promise in regenerative 
medicine because they are multipotent and capable of forming bone, cartilage, 
cardiomyocyte, and even hepatic tissue in vivo. Mesenchymal stem cells may also be a 
useful cell source for periodontal regeneration (Table 1). 
 
1.3.1 Non-craniofacial MSCs  
Kawaguchi et al. showed that bone marrow stromal cells transplantation promoted 
periodontal regeneration in experimental class III defects in beagle dogs. According to 
the histomorphometric measurement, bone marrow stromal cells treatment increase new 
cementum length and bone area up to 20% [14]. Using Green Fluoresent Protein (GFP) 
label technique, it was further conformed that these cells differentiated to cementum, 
periodontal ligament, and alveolar bone in vivo [15]. In a subsequent small clinical trial, 
autologous expanded bone marrow stromal cells mixed with Atelocollagen were 
transplanted into periodontal osseous defects at a periodontal surgery site, and all seven 
patients were  shown to have a good clinical course [16]. Another case report showed that 
transplantation of bone marrow stromal cells mixed with PRP (Platelet Rich Plasma) 
resulted in reduced bleeding, reduction of tooth mobility and reduced bone defect depth 
[17].   
 
Bone marrow stromal cells have also been shown to promote bone healing and dental 
implant osseointegration. In a series of studies, Yamada et al. used a combination of PRP 
as an autologous scaffold with in vitro-expanded bone marrow stromal cells to increase 
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osteogenesis in dental implant surgery [18-20]. This “autogenous injectable bone” 
treatment results in higher marginal bone levels, better bone-implant contact, and 
increase bone density compared to control. In our on-going clinical trial, bone marrow 
stromal cells transplantation is being tested to promote bone formation after tooth 
extraction for implant restoration. Bone marrow stromal cells were harvested from iliac 
crest and expanded in a special-designed bioreactor. Twelve days later, teeth extraction 
surgery was performed and the sockets were filled with autologous bone marrow stromal 
cells. Preliminary data showed that stem cell therapy is safe clinically, and it appears to 
augment bone regeneration in extraction sockets.  
 
Adipose tissue is another abundant resource for adult MSCs, and their greatest 
advantage is ease of access. Tobita et al demonstrated that, mixed with PRP, adipose-
derived MSCs could promote regeneration in rat periodontal palatal defects [21].  
 
1.3.2. Craniofacial MSCs 
Just as periodontal ligament is essential for osteogenesis and cementogenesis in 
periodontium development, cells derived from periodontal ligiment are necessary for 
regeneration of damaged periodontal tissue [22]. Transplantation of these cells has shown 
the potential to regenerate periodontal attachment apparatus in vivo [23-25]. Akizuki et al 
developed a PDL sheet using temperature-responsive cell culture dish technique and 
hyaluronic acid carrier [26]. After the transplantation of PDL cell sheet in rat and beagle 
dog model, significant cementum formation and anchoring PDL fibers were observed, as 
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well as new alveolar bone formation [26]. Using different labeling techniques, Lekic et al. 
showed that transplanted PDL cells integrate and differentiate into newly formed 
periodontal tissues [23].  
 
Specific cell types derived from periodontium have also been examined for their 
potential and roles in periodontal regeneration. Cementoblasts have a marked ability to 
induce mineralization in an ex vivo model [27] and in vivo in periodontal wounds [28]. 
However, when less-differentiated dental follicle cells are delivered in a similar fashion, 
these cells inhibit periodontal healing [28]. Similarly, progenitor cells isolated from 
dental follicle fail to form dentin, cememtun or bone in vivo, although they express high 
level of BSP, OCN and ALP [29]. These results suggest the selective behaviors of 
different cell types in periodontal regeneration. Recently, mesenchymal stem cells were 
isolated from periodontal ligament. Periodontal ligament stem cells (PDLSCs) express 
several mesenchymal stem cell markers, such as STRO-1 and CD44, and exhibit 
osteogenic, adipogenic, and chondrogenic characteristic under defined culture conditions 
(for reviews, see reference [10, 11]). Implanted into immuno-deficient mice, PDLSCs 
generated cememtum/PDL-like structures similar to native periodontium apparatus [30-
32]. In a porcine model of periodontitis, PDLSCs have been shown to regenerate new 
bone, cementum, and periodontal ligament in the periodontal defect area, and the height 
of the new alveolar bone was significantly higher than that in HA/TCP control group [33]. 
Combining PDLSCs and another stem cell population from the root apical papilla of 
human teeth (SCAP, stem cells from apical papilla) which contributes to dentin 
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deposition, Sonoyama et al. generated a bio-root structure encircling with periodontal 
ligament tissue [34].  
 
1.4. Gene therapy for the periodontal engineering 
      Gene therapy is defined as the treatment of disease or disorder by transferring genetic 
materials, which introduce, suppress, or manipulate specific genes that direct an 
individual’s own cells to produce a therapeutic agent [35]. Gene therapies have shown 
significant promise for the treatment of a wide range of diseases, such as adenosine 
deaminase deficiency [36], hemophilia B [37], X-linked adrenoleukodystrophy [38], etc. 
Gene therapy has also emerged as a promising strategy for the modulation of host-
response triggered by periodontal microbe and the regeneration of periodontium in 
periodontal diseases. Compared to traditional treatment (compounds and proteins), gene 
therapy has the following advantages: 1) Gene therapy provides a greater sustainability 
than that of single protein/compound application; While the half lives of pharmaceutical 
compounds or recombinant protein usually range from several hours to several days, viral 
vector genes can be expressed in vivo from weeks to years [39, 40]. 2) Gene therapy may 
be able to avoid issues associated with ex vivo protein expression and purification, such 
as palmitoylation and glycosylation [41]. 3) In theory, the temporally regulated delivery 
of genetic sequences encoding a combinatorial group of regenerative factors, which 
mimics the biology in natural healing, would be capable of an enhanced periodontal 
regeneration. 4) Combined with tissue engineering strategies, delivery of different genes 
9 
 
in a spacially regulated manner presents great potential in regenerating the multiple tissue 
interfaces in periodontium. 5) Gene therapy is more economical to patients.  
 
1.4.1. Gene delivery methods: 
        The preferred strategy for gene transfer depends on a number of factors: 1) the 
required duration of protein release (transient versus constitutive expression); 2) target 
cells (dividing and non-dividing cells, receptor expression); 3) host immune response to 
vectors; 4) route of gene delivery (ex vivo or in vivo); and 5) the morphology of the target 
site. For example, a horizontal one- or two-walled defect may require the use of a 
supportive carrier, such as a scaffold. Other defect sites may be conducive to the use of 
an adenoviral vector embedded in a collagen matrix, and a wide variety of viral and 
nonviral vectors have been developed for gene delivery. Examples of viral vectors are 
retroviruses, lentiviruses, adenoviruses (Ad) and adeno-associated viruses (AAV), and 
nonviral vectors include plasmids, DNA polymer complexes, nano/microbubbles and 
ultrasound, Zinc-finger nuclease and plasmid, etc. (Table 2) 
 
Retroviral vectors are single-strand RNA viruses that are replicated in a host cell 
through the enzyme reverse transcriptase to produce DNA from its RNA genome, and the 
resulting reverse-transcribed viral DNA is incorporated into the host cell's DNA strand by 
an integrase enzyme. When the genetically altered host cell divides later, its descendants 
contain the viral DNA copy. These vectors have significant advantages for sustained and 
efficient transgene expression that is ideal for the treatment of life-threatening hereditary 
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disorders, although most retroviruses can only infect dividing cells. Since the integrase 
enzyme may insert the DNA copy into an arbitrary position of the target cell DNA, 
endogenous gene expression maybe disrupted by insertional mutagenesis of a proto-
oncogene or tumor suppressor, and carcinogenesis may occur. 
 
Lentiviruses, such as the human immunodeficiency virus (HIV), are a specialized 
class of the retrovirus family and characterized by a long incubation period [35, 42]. 
Lentiviral vectors are one of the most efficient methods in gene delivery, being able to 
transfect both dividing and non-dividing cells [42]. These vectors are integrated into the 
host cell genome as well. In spite of the evidence that the insertion sites of lentivirus are 
more restricted than other retroviruses, the carcinogenesis induced by insertational 
mutation is still a hurdle for clinical application. Additionally, their HIV origin raises 
many concerns about the possibility that recombination events will lead to replication 
competent viruses.  
 
Adenoviruses are nonenveloped icosahedral viruses composed of a nucleocapsid and 
a double-stranded linear DNA genome [35]. In contrast to Lentiviruses, adenoviral 
vectors are attractive gene delivery vehicles due to a number of features: (1) Ads have 
high transduction efficiency in both dividing and nondividing cells; (2) Ads do not induce 
apparent phenotypic changes in transduced cells; and (3) Ads do not integrate into the 
host genome and remain episomal [43, 44]. These vectors may be  advantageous in 
periodontal tissue engineering because the transient expression of growth factors may 
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prevent the overgrowth of newly formed tissue. However, in large size craniofacial 
defects, the short-term gene expression may be insufficient to induce complete tissue 
regeneration [35]. One major concern regarding Ads gene delivery is the strong host 
immune response to viral capsid proteins. This has prompted attempts to modify the viral 
backbone in order to reduce immunogenicity [35]. Recently, several studies suggest that 
local therapeutic Ads appear to be safe and efficient in diabetic foot ulcer treatment and 
periodontal regeneration [43-45].  
 
Adeno-associated viurses derive from the parvovirus family and are small viruses 
with a single-stranded DNA genome [6]. AAV has attracted considerable interest from 
gene therapy researchers because of several significant advantages: 1) AAV is currently 
not related to any human disease; 2) AAV presents very low immunogenicity; and  3) 
AAV infects both dividing and nondividing cells. It has the ability to integrate its genetic 
material into the host cell genome at a specific site in the human chromosome 19, which 
makes it more predictable than retrovirus [46]. However, random integration of AAV 
DNA into the host genome is low but detectable. A recent report raised concerns over the 
clinical use of AAV vectors when mice developed hepatocellular carcinoma after 
neonatal injection of an AAV vector, which is associated with the insertion in a 6-
kilobase region of chromosome 12 [47]. Types of recombinant AAV have been 
developed either to remain extrachromosomal or integrate into nonspecific chromosomal 
sites [6]. One disadvantage of the AAV is that it is small and possesses the capacity to 
carry target DNA usually less than 5 kb [35].  
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Besides viral vectors, genetic material can be delivered into host’s cell by several 
nonviral alternatives, including naked plasmid, cationic lipids, polymers, peptides, and 
physical methods (electroporation and ultrasound) [48-51]. A major disadvantage for 
nonviral delivery methods is that nonviral gene carriers consistently exhibit significantly 
reduced transfection efficiency as they are hindered by numerous extra- and intracellular 
obstacles [51]. However, because of their low immunogenicity, lack of DNA insert size 
limitation, and potential for large-scale production, nonviral vectors will be given more 
consideration in the future, especially in the field of siRNA gene therapy [50-53]. In the 
past decade, a significant amount of research has focused on designing cationic 
compounds that can form complexes with DNA and can avoid both in vitro and in vivo 
barriers for gene delivery, and several compounds have been examined in clinical trials, 
such as Allovectin-7 [51]. It is worth mentioning that, due to the anatomic advantage, 
some non-invasive physical methods may be useful for delivering DNA to periodontium. 
Chen et al. reported that a gene transfer approach using ultrasound and 
nano/microbubbles leads to high gene expression in gingival tissue [49].    
 
1.4.2.  Scaffold protein LMP1 and osteogenesis  
      Using insulin receptor (INSR) as a bait in yeast 2-hybrid screen, Wu et al. first cloned 
a cDNA from HeLa cell encoded ENIGMA, named for its endocytic code recognition 
properties [54]. The ENIGMA protein is a representative of PDLIM protein family, 
which has conserved PDZ domain and LIM domains. LIM domains are cysteine-rich 
double zinc fingers, usually functioning in protein-protein interactions that are critical in 
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different cellular processes, such as organ development, cytoskeletal organization and 
oncogenesis [55]. It has been shown that the LIM domains of Enigma interact with 
several proteins, such as protein kinase C [56], Ret/pct2 oncogene [57, 58], and InSR 
(Table 3). The PDZ domain of Enigma binds to actin filaments [59, 60]. Although 
Enigma acts as a scaffold protein in the cytoplasm, its biological function is largely 
unknown. Enigma is highly conservative in different species. In zebrafish, Enigma 
knockdown appeared to be embryonic lethal shortly after the end of gastrulation [61]. In 
few surviving embryos, Enigma knockdown led to reduce tails and deformed somites.  
 
      In 1998,  Liu et al. cloned LIM mineralization protein-1 (LMP1) as a highly 
upregulated gene in the early stage of calvarial osteoblast differentiation [62]. Sequencing 
analysis showed that LMP1 encodes the same protein as Enigma. The expression of 
LMP1 was induced by glucocorticoid (GC) and BMP6, both at the mRNA and protein 
level. The expression pattern of LMP1 during fetal endochondral and membranous bone 
development was revealed by in situ hybridization: at rat embryonic day 14, LMP-1 
transcripts were expressed in mesenchymal tissue surrounding the cartilaginous anlage of 
immature bones and in the future joint spaces; later, as endochondral ossification 
progressed and the hypertrophic cartilage zone began to be replaced by mineralized bone, 
LMP-1 expression appeared in the mineralizing portion of the bone. In vitro experiments 
further demonstrated that LMP1 regulated the differentiation of osteoblast precursors. 
Over-expression of LMP in primary calvarial osteoblasts induced bone specific gene 
expression, such as osterix, alkaline phosphatase, osteocalcin, further promoting 
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mineralized nodule formation [63-65]. Blocking the expression of LMP1 by antisense 
oligonucleotides inhibits the differentiation of calvarial osteoblasts in vitro [62].  
  
      LMP1 has also been shown to promote bone formation in heterotopic (subcutaneous 
and intramuscular) and orthotopic (spine fusion) sites (Table 4). Using an adenoviral 
vector, LMP3, which is an osteogenic transcript variant of LMP1, was injected bilaterally 
into the exposed triceps surae musculature in mice. Bone formation was seen after 5 
weeks in all the mice injected with AdhLMP3, which was confirmed by radiography and 
Von Kossa staining in tissue sections [64]. The researchers reported that LMP gene 
transfer to mouse muscle results in rapid and efficient ectopic bone formation, relative to 
BMP-2 (all the animals injected with AdLMP3 had ectopic bone formation, whereas only 
half of AdBMP2 group formed bone). LMP1 gene delivery has also been shown to 
induce new bone formation in a spine fusion model [66]. Bone marrow-derived buffy-
coat cells from rabbits were transduced by AdLMP1 adenovirus, and then the cells were 
implanted during posterolateral arthrodesis. The results showed that LMP1 induces new 
bone formation and solid spine fusion, and the biomechanical quality of the regenerated 
bone was further confirmed.  
 
      Although LMP1 has been shown to regulate osteogenesis, much is still unknown 
about the mechanism of LMP1-induced osteogenesis. At least three transcript variants of 
LMP exist in humans: LMP1, 2, and 3 [63]. LMP1 and LMP3 are osteogenic, whereas 
the 119-base pair deletion of LMP2 leads to loss of osteogenic capability. It indicated that 
the 119-base pair area is critical for the osteogenetic characteristic (Figure 1). Recently, 
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the relative motif of LMP1 in this area has been identified. The motif directly interacts 
with the ww domain of Smurf1, which mediates Smad degradation, and leads to the 
accumulation of smad1 and smad5 in the cytoplasm which will prolong the BMP 
signaling effect [67, 68]. Small peptides containing this motif can mimic the ability to 
block Smurf1 from binding Smads in vitro. Overexpression of LMP1 in bone marrow 
stromal cells increases the amount of cytoplamic phophorylated Smad1. Taken together, 
LMP1 can increase the cell responsiveness to BMP signals. Other direct mechanisms 
may also be involved. It was found that BMP-2, BMP-4, BMP-6, BMP-7, and TGF-beta1 
expression was elevated in LMP1-overexpressed cells [69, 70]. So it is hypothesized that 
LMP1 may directly regulate the transcription control of osteogenesis. 
 
      Recently, it was found from immunohistological staining that LMP1 expressed in 
human predentin, odontoblasts, unmineralized reparative dentin, odontoblast-like cells, 
endothelial cells of blood vessels, and pulp fibroblasts, but not in mineralized mature 
dentin [71]. The same group also found that the mRNA of LMP1 was upregulated (about 
2 fold) in the osteolineage differentiation of human dental pulp cells [72]. However, the 
biological function of LMP1 in craniofacial and oral tissue development is still largely 
unknown.  
 
1.5 Statement of Purpose and Dissertation Overview  
      Periodontal disease is the leading cause of tooth loss in America adults because of 
severe alveolar (tooth-supporting) bone loss. Successful alveolar bone regeneration 
approaches for oral reconstruction remain a challenge for oral health care providers. 
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Periodontal ligament cells have the plasticity to differentiate into multiple distinct cell 
types including osteoblasts (bone-forming cells). New methodologies to target and 
deliver osteogenic factors to PDL cells will offer significant potential for alveolar bone 
regeneration. It has been shown that LMP induces osteolineage differentiation in 
mesenchymal stem cells. To date, mechanisms underlying LMP-induced osteogenesis 
remain unknown. My dissertation research continues to explore the biological function of 
LMP in PDL cells and bone marrow stromal cells, and further define its therapeutic 
potential for oral bone reconstruction. The research extends beyond a craniofacial bone 
emphasis to address essential mechanisms in the biology of bone formation.  
 
      Four core questions are clarified in my dissertation: 1) What are the gene expression 
profiles of LMP1 in craniofacial wound healing and periodontal disease? 2) How is the 
LMP gene regulated in the PDL cell? 3) What is the role of LMP in PDL cell 
proliferation and differentiation? 4) Will gene transfer of LMP stimulate ex vivo bone 
formation and promote oral implant osseointegration?  
 
      Four specific aims are included in this dissertation: 
 
      Specific Aim1: To identify the expression profile of LMP1 during craniofacial 
wound healing and periodontal disease. Hypothesis: The expression of osteogenic 
molecule LMP1 is regulated during tooth extraction healing and oral implant wound 
healing, and has an altered expression pattern in periodontal disease. In Chapter 2, I used 
laser capture microdissection (LCM) and real time quantitative RT-PCR to evaluate the 
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gene expression of LMP1 in healing area. Its expression under disease circumstance was 
assessed in ligature-induced and Porphyromonas gingivalis-lipopolysaccharide (Pg-LPS) 
induced experimental periodontitis. Knowledge about where, when and how LMP1 is 
regulated in periodontal wound healing and disease helps to shade light on the function of 
LMP1 in normal and pathological periodontium as well as during periodontal 
regeneration.  
 
      Specific Aim 2: To explore the effect of LMP1 in PDL cell proliferation and 
differentiation. Hypothesis: LMP is required for PDL cell proliferation and mineralized 
nodule formation in vitro.
 
 In Chapter 3, a loss-of-function strategy was used to 
characterize the function of LMP1 in PDL cell. The expression level of LMP in PDL 
cells was stably knocked down by RNAi. Cell proliferation and DNA synthesis capacities 
of knockdown cells were measured by crystal violet staining and 3[H]methylthymidine 
incorporation assay, respectively. Flow cytometry was performed to analyze the cell 
cycle change after LMP1 knockdown. Mineralization activity was assessed by Alizarin 
Red staining and Calcium measurement. My results showed that LMP1 gene knockdown 
impairs cell proliferation and delays osteogenic differentiation in PDL cells.  
      Specific Aim 3: To investigate the ability of LMP gene delivery to induce 
mineralization and promote bone formation. Hypothesis: Gene delivery of LMP1 and 
a truncated transcript variant, LMP3, is able to promote in vitro mineralization and 
stimulate ectopic bone formation. In Chapter 4, I first transduced PDL cells with 
adenoviral LMP1 and LMP3. Our results showed that AdLMP3, but not AdLMP1, 
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significantly stimulated matrix mineralization in vitro, which may be related to increased 
ALP and BSP expression. Next, I evaluated the potential of AdLMP1 and AdLMP3 to 
promote bone formation in an ex vivo tissue engineering model. LMP3 expressing PDL 
cells were delivered by polymer or collagen scaffolds and subcutaneously implanted in 
immunocompromised mice. Unexpectedly, AdLMP3 gene therapy alone or AdLMP3 
combined with AdBMP7 was not sufficient to promote ectopic bone formation in our 
model. Future studies are needed to identify the inhibitory factors which hinder the 
translation from in vitro to in vivo.   
 
      Specific Aim 4: To determine the regulatory mechanisms of LMP1 gene 
expression in PDL cells. Because LMP gene expression is up-regulated in the early 
phase of osteolineage differentiation of PDL cells, the hypothesis is that LMP1 is 
regulated by early signals in osteogenesis such as TGFβ-1. Studies in Chapter 5 
accomplished the following: 1) Determined the effect of TGFβ-1 on LMP expression in 
vitro and identified  dosage and time course of the effect. 2) Identified the signaling 
pathway mediating this effect. RNA interference (RNAi) and specific pharmaceutical 
kinase inhibitors were used to knockdown or block key modulators in canonical and non-
canonical TGFβ signaling pathways. The effect of TGFβ-1 on LMP1 RNA expression 
was confirmed by quantitative real time PCR. In addition, I showed that the activation of 
TAK1-JNK/p38 kinase cascade was necessary for induction of LMP1 gene expression by 
TGF-β1. TGF-β1 stimulated PDL cell proliferation, however, this effect was 
compromised when LMP1 was knocked down. I concluded that LMP1 is a downstream 
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target of TGF-β1, involved in PDL cell proliferation. My findings define a regulatory 
mechanism of LMP1 in PDL progenitor cells and other MSCs.  
 
      Understanding PDL cell biology is of critical importance to the oral health science 
community. The work described in this dissertation is particularly significant because 
knowledge gained contributes to establishing cell and molecular mechanisms used by 
LMP to regulate PDL cell activities, and further direct development of new therapeutics 
to repair bony defects in the oral and craniofacial complex due to disease, trauma or 
congenital abnormalities. This knowledge also contributes to better understanding of 
osteogenic differentiation of mesenchymal stem cells and provide the basis for novel 







Figure 1-1. Paradigm of periodontal tissue engineering. Six aspects to be considered for 
successful periodontal regeneration: appropriate cells, signals, blood supply, scaffold, 








Table 1: Selected examples of cell therapies for periodontal regeneration 









Auto Beagle dog Class III 
defects 
[14-16] 











Auto Porcine periodontal 
defects 
[33] 
 Allo Nude mice Ectopic [30] 
 Auto Dog Class II 
defects 
[74] 





Cementoblasts Allo SCID mice Ectopic [76] 





Dental follicle cells Allo SCID mice Ectopic [28, 76]  









Table 2. Viral and nonviral gene therapy vectors used in tissue engineering 
Vector Type Advantages Disadvantages 
Retrovirus Viral Nonimmunogenic Infects only dividing cells 
  Constitutive trangene 
expression 
Insertional mutagenesis 
Lentivirus Viral Infects dividing and non-
dividing cells 
Insertional mutagenesis 
  Infect wild range of cell types Potential pathogenicity 
  Low immune response Complex large scale 
preparation  
Adenovirus Viral Infects dividing and non-
dividing cells 
Potential immunogenicity 





Viral Infects dividing and 
nondividing cells 
Difficult to produce at 
high titers  
  Low immunogenicity   Small transgenes 
  Nonpathogenic in human   
Plasmid Nonviral Nonimmunogenic Low transduction 
efficiency 
  Nonpathogenic   
DNA polymer 
complexes 

























LIM2 NA [77] 
PKC (Protein 
kinase C) 
LIM NA [56] 
RET (Ret proto-
oncogene) 
LIM3 Mediate Mitogenic signal [58] 
TPM2 (β-
Tropomyosin) 
PDZ NA [59] 
APS (Adaptor 
protein with PH 
and SH2 
domains) 
LIM Actin cytoskeleton organization 
(Enigma overexpression in 3T3-L1 
adipocytes inhibits insulin-


















































Athymic rats Posterior arthrodesis 
of spine 
[78] 








































AdLMP3 Rat dermal 
fibroblast 
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GENE EXPRESSION PROFILE OF LMP1 IN CRANIOFACIAL WOUND 
HEALING AND PERIODONTAL DISEASE  
 
2.1 Abstract 
      LMP1 has been reported to be associated with osteoblast differentiation and bone 
formation. It remains elusive regarding the expression profiles of LMP1 in physiological 
and pathological craniofacial tissue. The objective of this study was to explore the gene  
expression pattern of LMP1 in alveolar bone wound healing processes and an 
experimental periodontitis model. Laser capture microdissection (LCM) and real time 
quantitative RT-PCR were performed to investigate the LMP1 expression in normal 
periodontium, and two alveolar bone healing models: tooth extraction socket healing and 
oral implant/bone osseointegration. The LMP1 expression was evaluated in inflamed 
gingival tissue in a rat periodontitis models induced by ligature placement or 
Porphyromonas gingivalis-lipopolysaccharide (Pg-LPS) injection. We showed that 
LMP1 was expressed at higher levels in PDL and gingival tissues compared to mature 
alveolar bone. After tooth extraction, the LMP1 expression was relatively low in early 
stage (coagulation stage), and it was slightly increased at day 7, 10 and 14. At an 
osteotomy defect area around dental titanium implant, LMP1 gene expression was 
relatively high at day 3, but steadily decreased at late stages. Very interestingly, LMP1 
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gene expression was up-regulated in the gingival tissue after experimental periodontitis 







      LMP1 (LIM mineralization protein-1) was first cloned as a highly upregulated gene 
in the early stage of calvarial osteoblast differentiation [1]. Sequencing analysis showed 
that LMP1 encodes the same protein as ENIGMA, which is a intracellular scaffold 
protein involved in cell proliferation, differentiation and glucose uptake [2-5]. During 
embryonic development, LMP1 is expressed in mesenchymal tissue surrounding the 
cartilaginous anlage of immature bones and in the future joint spaces [1]. Although 
several studies showed that LMP gene therapy appears to be promising for bone 
regeneration, very little is known about when, where and how LMP1 gene expression is 
regulated in physiological and pathological circumstances, specifically, in periodontal 
disease and wound healing.  
 
      Tooth extraction is the most commonly performed surgical procedure in humans. The 
healing of an extraction socket starts with the formation of coagulum, followed by 
infiltration of provisional connective tissue which is subsequently replaced by newly 
formed woven bone, and  ultimately by lamellar bone and bone marrow [6]. Tooth 
extraction socket healing has been intensively studied in the last half century [7-10], 
however, most of the studies focused on histological aspects of the healing process. Very 
few studies attempted to understand the dynamic gene expression profiles in the wound 
healing site after tooth removal.  
 
      Oral implants have become a standard treatment modality for tooth loss caused by 
periodontal disease, trauma, or some other reasons. The long-term success of implant 
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anchorage in alveolar bone is believed to be dependent on “osseointergration”, which 
histologically is defined as 'direct bone-to-implant contact' without soft/connective tissue 
intervention [11, 12]. The processes of osseointegration involves a series of events 
including early protein and  cell apposition, necrosis and resorption of traumatized bone 
around the titanium body, subsequent de novo bone formation and maturation to achieve 
the primary and secondary dental implant stability [11, 12].  
 
      The purpose of this study was to investigate the gene expression profile of LMP1 on 
craniofacial wound healing (tooth extraction socket healing and oral implant/bone 
osseointegration) and an experimental periodontitis model. In addition, the expression 
profile of a group of genes associated with bone healing, such as growth factors, 
transcription factors and chemokines, was also evaluated. Knowledge from this study will 
help us to better understand the function of LMP1 and shed light on the design of future 
LMP1-based gene therapies.  
 
2.3 Results 
Stronger LMP1 expression in periodontal ligament and gingiva compared to mature 
alveolar bone 
      At first we tested the gene expression profile of LMP1 in normal periodontium. 
Because suitable LMP1 antibodies are not available for immunohistological staining, we 
used laser capture microdissection (LCM) to collect PDL, gingival and alveolar bone 
tissues from decalcified rat maxillae sections. In order to validate the technique, genes 
with distinct expression profiles in these three tissues were tested (Figures 2-3). 
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Keratin14, an epithelial marker, was highly expressed in gingiva but present only at low 
levels in bone and PDL; Osteocalcin (OCN), a primary bone marker, was highly 
expressed in alveolar bone; Periostin, a marker for ligature and PDL, was highly 
expressed in the PDL samples. These results suggested that RNA retrieved from laser 
capture microdissection was still suitable for gene expression analysis. LMP1 gene 
expression in the above three tissues was also investigated. We showed that LMP1 is 
expressed at higher levels in PDL and gingival tissues compared to mature alveolar bone 
(Figures 2-3).  
 
LMP1 expression during tooth extraction socket healing 
      Next, we looked for possible regulation of LMP1 during wound healing following 
tooth extraction. The rat first maxillary molars were extracted, and after 3, 7, 10 and 14 
days, animals were sacrified. Histologically, the extraction sockets followed a well-
defined healing sequence (Figures 2-4A). At day 3, large clots were seen in the sockets, 
surrounded by scattered neutrophils and a large amount of mesenchymal cells (severed 
PDL). At day 7, the coagulum area became relative small, and more fibroblasts appeared 
in sockets, and newly formed bone which is less stained could be easily seen. At day 10, 
clots were replaced by fibroblasts and new bone. At day 14, the sockets were completely 
filled by new bone and bone marrow.  
 
      Tissues in the extraction sockets were dissected by laser capture at the above time 
points. We found that LMP1 expression was relatively low in early stages (coagulation 
stage), and it was slightly increased at days 7, 10 and 14 (Figure 2-5). We also analyzed 
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the expression profile of genes associated with wound healing. Four categories of genes 
were examined: growth factors, extracellular matrix proteins, chemokines, and 
transcription factors. In the 19 genes we tested, three expression patterns were evident 
(Figure 2s-5): 1) genes that are highly expressed at early time points and are down-
regulated at later stages. Chemokines IL-1β, CXCL2 and CXCL5 belong to this category; 
Wnt5a and Wnt4 seemed to decrease as well during healing; 2) Genes that are slowly 
increased during the healing process: Growth factors (BMP4, BMP7, Wnt10b and 
VEGF), transcription factors (Runx2), and extracellular matrix proteins related to 
mineralized tissue (OPN and OCN) are in this group; Very interestingly, CXCL12 (SDF-
1) gradually increases during extraction socket healing. TGF-β1 increases at a mid stage 
of healing (day 10) and then decreases. Similarly, Periostin, a target gene of TGF-β1, had 
the same expression pattern; 3) Genes that are constitutively expressed. Tendon specific 
transcriptional factor Scx appeared to be in this group.   
 
LMP1 gene expression gradually decreased during healing after osteotomy around 
implants 
      We also examined the LMP1 gene expression during the bone defect healing around 
titanium implants. Histologically, the healing after osteotomy is similar to extraction 
socket healing except for the following differences: 1) the healing seems delayed; 2) 
more infiltration by inflammatory cells is seen in early stages (Figure 2-4B). The same 19 
genes were also analyzed (Figure 2-6). Interestingly, most genes follow the same pattern 
as of extraction socket healing. However, LMP1 gene expression was relatively high at 
day 3, but steadily decreased at late stages. 
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 LMP1 gene expression was up-regulated in the experimental periodontitis 
      In a ligature-induced periodontitis model, LMP1 expression in gingival tissue was 
upregulated 3 days after ligature placement, peaked at day 7, and dropped down to 
baseline at 14 days (Figure 2-7A). Similarly, in Pg-LPS-induced-periodontitis models, 
LMP1 gene expression in gingival tissue increased significantly 24 hours after LPS 
injection, and the effect lasted until 48 hours (Figure 2-7B). It was suggested that LMP1 
may be related to the immune response induced by pathogens.  
 
2.4 Discussion 
      LCM is a method to procure pure subpopulations of tissue cells of interest under 
direct microscopic visualization [13, 14]. Combined with other sophisticated molecular 
biology technologies such as DNA sequencing, cDNA array, DNA microarray, real time 
PCR and two-dimensional polyacrylamide gel electrophoresis, etc, this technology is a 
powerful tool to analyze in vivo cell function and gene expression [15, 16]. LCM has 
been extensively used in soft tissue samples, however it is still a challenge for 
mineralized hard tissue due to the need for decalcification. Although it has been reported 
that successful RNA extraction and RT-PCR could be performed from fresh frozen 
undecalcified tissue [17], this method is not very practical for bone and teeth tissue. Some 
studies had reported that RNA can be retrieved from decalcified samples [15].  Here, we 
were able to use LCM to dissect decalcified maxillae samples and successfully analyze 
gene expression from different area of interest. LCM provides a unique opportunity to 
clearly dissect the tooth extraction healing areas and implant osseointegration sites. In the 
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future, if we perform fluorescent bone labeling techniques after surgical procedures, it 
will provide a clearer border to guide the laser capture microdissection.   
 
      In this study, we found that, in normal periodontium, the expression level of LMP1 is 
higher in PDL and gingival tissue than in mature alveolar bone, which is somehow 
surprising to us. However, this result is consistent with our in vitro finding that LMP1 is 
expressed at lower levels in the final stage of pre-osteoblast differentiation, specifically in 
PDL cells (see Chapter 3). Taken into account the fact that LMP-1 was expressed in 
higher amounts and showed a higher degree of variation in bone samples from young 
patients than old individuals [18], it is suggested that LMP1 may not be critical in mature 
bone.  
 
      So far there is very limited information regarding gene expression profiles during the 
tooth extraction socket healing, and no information was reported about the regulation of 
LMP1 during bone wound healing. Taking advantage of LCM, we found that LMP1 
appear to be slightly increased during tooth extraction healing although there was no 
statistical significance due to the large variability in the small sample. At the same time, 
valuable information about the gene expression pattern of key players in alveolar bone 
healing were provided in this study. We found that chemokines are highly expressed at 
the early stage of healing which is consistent with histological finding. Growth factors 
and angiogenesis factors showed significant increases after the early inflammation stage 
and kept in a relative high level until the wound healed. Very interestingly, we found that 
Wnt10b and CXCL12/SDF-1 were gradually increased during bone healing. More studies 
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are needed in the future to characterize the function and possible application of these 
morphogen and stem cell chemoattractants in alveolar bone healing. 
 
      We found that the gene expression pattern of LMP1 in the osteotomy defect area 
around titanium implants was different compared to the tooth extraction socket. We still 
don’t understand this phenomenon. One possible explanation is that more immune cells 
infiltrate into the implant defect area which might lead to increased LMP1 expression in 
this area because LMP1 is highly expressed in leukocytes.   
 
      We found that LMP1 is upregulated in inflamed gingival tissue. This suggests that 
LMP1 may play a role in host immune modulation. It has been shown by Liu et al. that 
LMP1 is highly expressed in portions of the immune system, such as lymph nodes, 
thymus, tonsils, spleen and leukocytes [19] . Recently it was reported that LMP-1 has an 
anti-inflammatory effect which is due to the inhibition of NO production by suppression 
of NF-kappaB activation [20]. Another clue suggesting that LMP1 is associated with 
immune cells relies on the fact that LMP1 is regulated by TGF-β1 [21], which is a potent 
immune suppressor and plays an important role in immune cell differentiation. Taken 
together, it will be very interesting to determine the role of LMP1 host response to 
pathogens, especially in periodontal disease.  
 
      In summary, for the first time, this study provided the gene expression profiles of 
LMP1 in normal periodontium. We also report its expression pattern in bone wound 
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healing and disease situations. This information will help better understand the function 
of LMP1 during oral and craniofacial bone repair.    
 
2.5 Materials and methods 
Experimental design 
      A total of 36 male Sprague–Dawley rats were used in this study and the general 
timeline is shown in Fig 2-1. Briefly, the first molar teeth (M1) at one side of maxillae in 
all rats were extracted. After 1 month, osteotomy was performed on the healing sites and 
implants were placed. At the same time, first molar teeth (M1) at the other side of the 
maxillae were extracted. 3, 7, 10, 14 day following the surgeries, rats were euthanized 
and the maxillae were removed. In each time point, samples from 6 animals were used 
for laser capture microdissection and RNA extraction followed by qRT-PCR. 
Histological evaluation was performed on the other 3 animals (H&E staining for tooth 
extraction sites and back-scatter SEM for bone-implant osseointergration). All procedures 
were approved by the University of Michigan Committee of Use and Care of Animals. 
Animals were anesthetized under general anesthesia with ketamine (50 mg/kg) and 
xylazine (10 mg/kg). 
 
Tooth extraction, defect creation, implant placement 
      The entire surgical procedure is shown in Figure 2-2. Briefly, the maxillary first 
molar teeth (M1) were extracted using an atraumatic technique. The extraction sockets 
and soft tissues were allowed to heal for approximately 30 days. After healing, an 
osteotomy was created using a custom drill-bit as previously described [11]. The drill-bit 
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was designed with a 0.95-mm diameter, 1mm long-apical portion and a 2.2-mm diameter, 
1 mm long at the coronal aspect. The apical part of the drill created an osteotomy for 
initial fixation and the coronal part of the drill created a circumferential osseous defect 
before dental implant installation. Custom-fabricated, sterile, commercially pure, solid-
cylinder titanium implants with SLActive® surface (chemically modified surface by 
extensive hydroxylation/hydration with an average 4.1-4.7 μm roughness) designed 
(Institut Straumann AG, Waldenburg, Switzerland) to the appropriate dimensions for 
placement into the rat maxillae (2 mm in length and 1 mm in diameter). The implants 
were press fit into position and evaluated for primary stability. The surgical field was 
closed by means of tissue glue (PeriAcryl, n-Butyl Cyanoacrylate, GluStitch Inc., Delta, 
B.C., Canada). The animals were observed post-operatively on a heating pad until fully 
alert to ascertain their response to surgery. To maintain energy and prevent infection, 
animals were given a 10% dextrose solution containing 268 g/L ampicillin for one week 
post-surgery.  
 
Laser capture microdissection (LCM) 
      The animals were sacrificed by CO2 euthanasia at the designated time points 
following surgery. Block biopsies were harvested, and immediately fixed with 10% 
phosphate-buffered neutral formalin for 24 hours. Biopsies were decalcified for 14 days 
in 10% EDTA solution. After implants were gently removed, biopsies were embedded in 
paraffin, cut sagittally along the axis of the tooth into 7 µm sections by microtome. Laser 
capture microdissection (LCM) was performed to dissect out the areas of interest (Fig 2). 
Six different tissues from each animal were collected: osteotomy defect area (A), 
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osseointegration site (B), tooth extraction healing site (C), gingival tissue (D), periodontal 
ligament (E), native alveolar bone in non-surgical area (F).  
 
Animal model of experimental periodontal disease  
      Two models were used to induce periodontal disease and bone loss in Sprague-
Dawley rats. 1) Ligature model.  The use of ligatures elicits the rapid loss of 
approximately one-half of the bone support over a period of 3 to 6 weeks, which is 
related to the inflammatory process induced by increased microbial biofilm formation 
around the cervix of the teeth and an acute physical irritation factor as a consequence of 
the subgingival placement of the ligature. 3/0 cotton ligatures were placed bilaterally into 
the gingival sulci of the mandibular first molar teeth. The ligatures were evaluated twice 
weekly, gently displaced apically into the gingival sulci to ensure a subgingival position, 
and replaced when necessary. 2) Porphyromonas gingivalis-lipopolysaccharide (Pg-
LPS)-induced periodontal disease model. Experimental periodontal disease induction was 
performed by administering 10 μl of Pg-LPS (1.0 mg ml−1) into four palatal gingival 
tissue sites (total of 40 μl per animal) at the base of the interproximal gingival papillae 
between maxillary molars bilaterally [22]. The injections were performed three times 
weekly using custom-designed 0.375 in × 33 ga, 30° bevel needles attached to a 50  μl 
Hamilton syringe (Hamilton Company, Reno, NV, USA). Gingival tissue biopsies were 
harvested from a standardized region of the palatal region of the maxillary molar teeth, 
comprising an ~5 × 2 mm rectangular area from the medial of the first molar to the distal 





      Total RNA samples were extracted with RNAeasy kit (Qiagen, Maryland) according 
to the manufacture’s instruction. RNA was subjected to reverse transcription in a 50μl RT 
reaction using TaqMan Reverse transcription reagents (Applied Biosystems, Foster city, 
CA). cDNA was generated using random hexamer primers and oligo-T primers with 2:1 
ratio). After that, a preamplification kit was used to boost the low cDNA amount from 
LCM dissection (Applied Biosystems). For quantitative real-time PCR, the generated 
cDNA was analyzed, in triplicate, with the Master Mix (Applied Biosystems) in the 
ABI7500 Sequence Detection System. The results were normalized with 18s transcript. 
The primers and probes were ordered from Applied Biosystem.  
 
Statistical analysis 
      Statistical analysis was performed using GraphPad Prism software. All data are 
presented as the mean ± SD. The significance of the differences was determined by using 
the two-tailed Student's t-test and one-way ANOVA. P-values less than 0.05 were 







Figure 2-1 Experimental design for investigation of gene expression profiles in 
craniofacial wound healing. The left maxillary first molar (M1) were extracted using an 
atraumatic technique. The extraction sockets and soft tissues were allowed to heal for 28 
days. After healing, an osteotomy was created using a custom step-drill and the right 
maxillary molars were extracted at the same time. The animals were euthanized at day 3, 
7, 10, 14 days, and the maxillae were fixed. For the implant placement site, backscattered 
SEM measurements, H&E staining, and laser capture microdissection were performed. 
For the tooth extraction sites, only H. & E. staining, and laser capture microdissection 









Figure 2-2 Surgical procedures of tooth extraction and titanium implant placement. 
(A) Healthy maxillary first molar (M1) before extraction. (B) M1 was extracted, and five 
root sockets were clearly seen. (C) After 1 month, the mucosa and alveolar bone heal. (D) 
A full thickness flap was created from in the direction of palatal to buccal. (E) Alveolar 
bone was exposed. (F) An osteotomy was created using a custom step-drill. The drill-bit 
was designed with a 0.95-mm diameter, 1 mm long-apical portion and a 2.2-mm 
diameter, 1 mm long at the coronal aspect. (G) Implant was placed. (H) The flap was 
place back and glued.  The scheme shows the position and size of the osteotomy. The 
apical part of the drill created an osteotomy for initial fixation and the coronal part of the 










Figure 2-3. Gene expression pattern of LMP1 in healthy periodontium. LCM was 
utilized to collect gingiva, periodontal ligament, alveolar bone tissues from decalcified 
maxillae sections. RNA extraction and RT-PCR were performed to detect genes markers 
in different tissue. Keratin 14: an epithelial marker. OCN: osteocalcin, a primary bone 
marker. Periostin, a marker for ligature and PDL. Stronger LMP1 expression in 
periodontal ligament and gingiva compared to mature alveolar bone. a: p<0.05 compared 







Figure 2-4 Histology view of the healing after tooth extraction (A) and osteotomy 
and implant placement (B).  (A) H. & E. staining images of extraction socket 3, 7, 10, 
14 days after surgery. (B) H. & E. staining images of osteotomy defect around implant. 
Implants were pushed out already. *: original implant sites.  The dotted lines show the 





Figure 2-5 Gene expression profiles during tooth extraction socket healing. LCM 
was performed to dissect the extraction socket 3, 7, 10 and 14 days after tooth removal. 
qRT-PCR was used to analyze genes related to wound healing. Group 1: growth factors. 
Group 2: extracellular matrix proteins. Group 3: chemokines. Group 4: transcription 
factors and other intracellular scaffold protein. LMP1 expression was relatively low in 
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early stage (coagulation stage), and it was slightly increased at day 7, 10 and 14. a: 
p<0.05 compared to day 3; b: p<0.05 compared to day 7; c: p<0.05 compared to day 10; 
d: p<0.05 compared to day 14; e: p<0.01 compared to day 3; f: p<0.01 compared to day 7; 





Figure 2-6 Gene expression profiles during healing in the osteotomy area around 
titanium implants. LCM was performed to dissect the defect area around implants. RT-
PCR was used to analyze genes related to wound healing. Group 1: growth factors. Group 
2: extracellular matrix proteins. Group 3: chemokines. Group 4: transcription factors and 
other intracellular scaffold protein. LMP1 gene expression gradually decreased during 
healing after osteotomy around implants. a: p<0.05 compared to day 3; b: p<0.05 
compared to day 7; c: p<0.05 compared to day 10; d: p<0.05 compared to day 14; e: 
p<0.01 compared to day 3; f: p<0.01 compared to day 7; g: p<0.01 compared to day 10; h: 






Figure 2-7 LMP1 gene expression is up-regulated in experimental periodontitis. Two 
models were used to induce periodontal disease and bone loss in Sprague-Dawley rats. (A) 
Cotton ligatures were placed bilaterally into the gingival sulci of the mandibular first 
molar teeth. The use of ligatures elicits the rapid bone loss due to the inflammatory 
process induced by increased microbial biofilm formation around the cervix of the teeth 
and an acute physical irritation factor as a consequence of the subgingival placement of 
the ligature.  (B) Porphyromonas gingivalis-lipopolysaccharide (Pg-LPS was injected 
into four palatal gingival tissue sites at the base of the interproximal gingival papillae 
between maxillary molars. Gingival tissue biopsies were harvested from a standardized 
region of the palatal region of the maxillary molar teeth. RT-PCR was performed to 
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LMP1 REGULATES PERIODONTAL LIGAMENT PROGENITOR CELL 
PROLIFERATION AND DIFFERENTIATION  
 
3.1 Abstract 
LMP1 is an intracellular scaffold protein that contains a PDZ domain and three LIM 
domains. LMP1 has multiple functions including regulating mesenchymal stem cell 
(MSC) osteogenesis. Gene delivery of LMP1 induces bone formation in vivo in 
heterotopic and orthotopic sites. However, little is known about the physiological 
function of LMP1 in MSCs. Periodontal ligament (PDL) cells are a unique progenitor cell 
population that can differentiate into multiple cell types, including osteoblasts, adipocytes 
or chondrocytes. This study sought to determine the physiological function of LMP1 in 
PDL cells. We show that LMP1 is upregulated in early stage of PDL cell osteogenic 
differentiation. Stable gene knockdown of LMP1 by shRNA inhibits DNA synthesis and 
corresponding cell proliferation in PDL cells, and further leads to decreased 
mineralization in vitro. Overexpression of LMP1 increases cell proliferation, and PDZ 
and ww-interacting domains are not enough to mediate this effect. We conclude that 
LMP1 is involved in PDL cell proliferation. Our findings advance the understanding of 




The intracellular protein LMP1 (LIM domain mineralization protein) belongs to the 
PDLIM protein family, which consists of a PDZ domain in the N-terminus and three LIM 
domains at the C terminus [1, 2]. Increasing evidence suggests that LMP1 regulates the 
osteogenesis program in MSCs. For example, overexpression of LMP1 in bone marrow 
stromal stem cells, calvarial osteoblasts, and dermal fibroblasts initiates osteolineage 
differentiation in vitro [2-5]. Gene delivery of LMP induces efficient bone formation in 
vivo in heterotopic (subcutaneous and intramuscular) and orthotopic (spine fusion and 
bone fracture healing) sites [5-8]. Although the potential application of LMP1 in bone 
regenerative medicine, the physiological roles of LMP1 in MSCs remain to be established. 
So far, LMP1 knockout mice still haven’t been developed, and LMP1 knockdown in 
zebrafish is embryonically lethal [9].  
 
Periodontal ligament (PDL) cells are a unique mesenchymal stem cell population that 
can differentiate into multiple cell types, such as osteoblasts, adipocytes, and neurons [10, 
11]. The PDL cell is a promising cell source for periodontal hard and soft tissue 
regeneration [12, 13]. This study sought to determine the physiological function of LMP1 
in PDL cells proliferation and differentiation. We stably knocked down LMP1 by shRNA. 
Gene knockdown of LMP1 inhibits cell proliferation and DNA synthesis in PDL cells, 
and further impairs osteogenic differentiation. Overexpression of LMP1 in PDL cells 
stimulates proliferation, which is not dependent on its PDZ and ww-interacting domains. 
Our findings may help in the better understanding of the role of LMP1 in PDL cells 




LMP1 is upregulated in the early stage of osteogenic differentiation of PDL cells.  
PDL cells are a mixed cell population from the tooth-supporting apparatus. It is well 
established that these cells can differentiate to multiple cell types [10], and we also 
confirmed that PDL cells from different patients can differentiate to osteoblasts and 
adipocytes. We next analyzed the gene expression of LMP1 during osteogenic 
differentiation. As shown in Figure 3-1A, LMP1 expression is upregulated at 3 d and 
decreases at later time points. The same pattern was seen at protein level as well (Figure 
3-1B). This result reveals that LMP1 is involved in the early stage of osteogenic 
differentiation of PDL cells.  
 
shRNA-mediated silencing of LMP1 impairs PDL cell proliferation.  
In order to better understand the function of LMP1 in PDL cells, we used RNAi 
technology to knock down LMP1 gene expression in vitro. Two double-stranded shRNAs 
targeting LMP1 and a scrambled shRNA were designed and cloned into a retroviral 
system. After retrovirus infection and puromycin selection, resistant clones were pooled. 
The LMP1 expression was verified at mRNA (Figure 3-2A) and protein (Figure 3-2B) 
levels. LMP1 knockdown of PDL cells demonstrated lower proliferation rates when 
compared to controls. When we seeded the same number of cells in 12-well-plates and 
induced them towards osteolineage differentiation, LMP1 knockdown cells demonstrated 
a slower proliferation rate compared to control (Figure 3-2C). At day 10, cells were fixed 
and stained with crystal violet staining and less staining was found in knockdown cells 
(Figure 3-2D, E). Consistent with this obervation, LMP1 knockdown in PDL cells 
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inhibited DNA synthesis which was shown by 3H methyl thymidine incorporation assay 
(Figure 3-2F). Since this effect can also be explained by the increase of apoptotic cells 
while LMP1 was knocked down, we tested the expression of an apoptosis marker 
Caspase-3. Caspase-3 is a critical executioner of both intrinsic and extrinsic apoptosis, as 
it is responsible for the proteolytic cleavage of many key factors involved in apoptosis 
[14]. Activation of caspase-3 requires proteolytic processing of its inactive zymogen into 
activated p17 and p12 fragments [14]. There is no significant increase of cleaved 
caspase-3, which indicates that the LMP1 knockdown effect may be related to impaired 
proliferation (data not shown). Actually, by RT-qPCR, we confirmed that LMP1 
knockdown resulted in less cell expression of Cyclin D1 and Cyclin B1 compared to 
control (Figure 3-2G). FACS analysis further showed that greater degree of LMP1 
knockdown of cells were blocked at G1 phase compared to scrambled control cells (Table 
1). Taken together, knockdown expression of LMP1 in PDL cells impairs cell 
proliferation.  
 
LMP1 silencing delays osteogenic differentiation. 
We further determined whether gene knockdown of LMP1 affects osteogenic 
differentiation in PDL cells. Control shRNA showed similar levels of ALP staining and 
mineralization capability when compared to non-treatment controls (data not shown). 
However, less ALP positive cells were seen when LMP1 was stably knocked down by 
shRNA, and the ALP activity was lower in knockdown cells (Figure 3-3A). Consistent 
with this, less mineralized nodules were observed in LMP1 knockdown PDL cells at late 
stage of PDL osteogenic differentiation, which was shown by Alizarin Red staining and 
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extracellular measurement (Figure 3-3B). We further used RT-qPCR to examine several 
gene markers involved in PDL differentiation. We found that LMP1 knockdown of PDL 
cells demonstrated delayed expression of Runx2 and Osterix (Figure 3-3C). Collagen1A1 
(Col1A1) and Bone sialoprotein (BSP) tended to decrease in LMP1 knockdown cells as 
well. These results suggest that LMP1 knockdown retards the early osteogenic 
differentiation of PDL cells in vitro.  
 
PDZ and ww-interacting domains are not sufficient to stimulate cell proliferation  
Our results suggest that LMP1 is required for PDL cell proliferation. To examine 
whether LMP1 transgene can enhance PDL cell proliferation, we stably overexpressed 
LMP1 in PDL cells using a retroviral system. We also established stable PDL cell lines 
expressing a truncated form of LMP1 only containing the first 144 amino acid residues, 
which consists of PDZ domain and ww-interacting motifs, but not any LIM domain 
(Figure 3-4A). The antibody we used can recognize the N-terminus of LMP1, which 
made it possible to detect both forms in Western blot (Figure 3-4B). The full length 
LMP1 is about 50 kD, and the truncated form in about 16kD. As shown in Fig 4C, 
expression of the full length LMP1 significantly promoted PDL cell proliferation, 
however, the truncated form had limited effect. We didn’t see significant cell death during 
cell culture. Consistent with this, there were no significant increase in the cleaved 
fragments of caspase-3, which are the active forms, in control and LMP-t PDL cells (data 
not shown). By 3H methyl thymidine incorporation assay we further showed that DNA 
synthesis is upregulated in LMP1 overexpression PDL cells (Figure 3-4D). Therefore, our 
result suggests that PDZ and ww-interacting domains are not enough to stimulate the 
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mitotic effect. This is also supported by Durick et al reporting that LMP1 mediates the 
mitogenic signaling in mouse fibroblasts [15]. 
 
3.4 Discussion 
Although it has been reported that LMP1 plays a role in osteoblast differentiation [4, 
16, 17], its physiological function remains unclear. Because LMP1 is highly expressed in 
periodontal ligament tissue and it is up-regulated at early stages of osteogenic 
differentiation in PDL cells, we further explore the possible function of LMP1 in PDL 
cells. By stable expression of two shRNAs in PDL cells, we observed that the 
proliferation and DNA synthesis capability decreased in LMP1 knockdown PDL cells 
compared to non-target shRNA control. LMP1 knockdown appears to lead to longer G1 
phase in PDL cells. On the other hand, using a “gain-of-function” strategy, we showed 
that LMP1 overexpression significantly promotes PDL cell proliferation. Consistent with 
this finding, Yoon et al showed that LMP1 transfection induced mild but significant 
increased in DNA synthesis in intervertebral disc annulus cells [18]. These results suggest 
that LMP1 is necessary and sufficient for PDL cell proliferation.  
 
It is not clear how LMP1 participates in cell proliferation. By the truncated mutation 
experiment, we found that PDZ and ww-interacting domains are not enough to induce the 
mitogenic effect of LMP1. This finding is consistent with the hypothesis that LMP1 
exerts its function as a scaffold protein that mediates mitogenic signaling activated by 
growth factors. Durick et al showed that LMP1 mediates the mitogenic signaling by 
Ret/ptc2 in mouse 10T1/2 fibroblasts. LMP1 binds to Ret/ptc2 via its second LIM 
59 
 
domain and functions as an adaptor protein, with the PDZ domain of LMP1 anchoring 
the LMP1-Ret/ptc2 complex to the cell periphery [1, 15]. On the other side, 
overexpression of a truncated form of LMP1 without LIM domains inhibited the 
mitogenic effect of Ret/ptc2 [15]. In future study, it will be important to identify the 
binding partners of LMP1 in order to characterize its mechanism in PDL cell 
proliferation. 
 
Osteogenesis is a complicated process that involves cell proliferation, differentiation 
and subsequent nodule formation and mineralization. Our data showed that LMP1 gene 
knockdown impairs PDL proliferation, and consequently the mineralization was delayed. 
This is consistent with the observation from Boden et al [2]. On the contrary, when stably 
overexpressed in PDL cells, LMP1 did not seem to promote mineralization nodule 
formation in vitro and bone formation in vivo (data not shown). Actually, constitutive 
expression of LMP1 tends to inhibit mineralization in PDL. More study should be done 
to further demonstrate why this happens. One possible explanation is that 
LMP1-overexpressing PDL cells tend to maintain in a proliferating stage, thus less cells 
will exit the cycle into differentiation.  
 
Besides this role in osteogenesis, LMP1 might be involved in the adipocyte 
differentiation as well. It has been shown that LMP1 mRNA expression increases in 
adipose tissue of diabetic obese patients. LMP can bind to insulin receptor, and it also 
interacts with adaptor protein through PH and SH2 domains (APS) to control 
insulin-induced actin cytoskeleton remodeling and glucose transporter 4 translocation in 
60 
 
3T3-L1 adipocytes. In the future it will be interesting to explore the function of LMP1 in 
adiopogensis. 
 
We conclude that LMP1 is required for PDL cell proliferation and osteolineage 
differentiation. With the limits of the lack of an in vivo LMP1 knockout model, our 
findings suggest a possible physiological function of LMP1 in PDL progenitor cells.  
 
3.5 Materials and methods 
Cell culture 
The isolation of human periodontal ligament (PDL) cells for these studies was 
approved by the University of Michigan Health Sciences Institutional Review Board. 
PDL cells were obtained from extracted third molar or premolar teeth of healthy patients 
and cultured in 100 mm tissue culture dishes in a DMEM medium supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin [10]. PDL cells from 5 patients (Age 
range 20-50 years) were pooled together and were used at passages 2 to 6.  
 
Short Hairpin RNAs (shRNA) and Retroviral Infection and Constructs 
Retrovirus-based shRNA knockdown system (pSIREN-RetroQ vector, from Clontech 
(Mountain view, CA) was utilized to stably knock down endogenous LMP1 expression. 
Target sequences were selected with software available on the Dharmacon web sites. 
Oligonucleotides synthesized by Invitrogen (Carlsbad, CA) were annealed and subcloned 
into retroviral vectors at EcoRI and BamHI sites. The two target sequences to LMP1 
identified were: si1: 5'-gtttgagtttgctgtgaagtt-3' and si2: 5'-gcaagagccgagataaagcca-3'. 
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Non-target scramble shRNA sequence is: 5'-aaaaccgacggctatctct-3'. shRNA expression 
vectors were delivered into PDL cells using retroviral transduction according to the 
manufacturers directions. Briefly, PDL cells were transfected by retrovirus twice over 36 
hours, with a 12 hour interval between infections. Next, puromycin (1μg/ml) was added 
for 3 days. Resistant clones were pooled together for subsequent experiments. At least 6 
independent transfections had been performed and the efficiency and specificity of 
suppression by shRNAs were evaluated with analyses of protein and/or RNA levels as 
indicated.  
 
LMP1 gene overexpression in PDL cells 
Full length LMP1 gene was cloned from MG63 cells by RT-PCR, then was inserted 
into retrovirus vector pQC-XIN (Clotech, Mountain view, CA). A truncated form without 
any LIM domain was generated by PCR. After that, retrovirus production and 
transfection was performed following the similar protocol, and PDL cells were selected 
by G418 for 10 days.  
 
[methyl-3H]thymidine incorporation assay 
PDL cells with stable shRNA expression were seeded in 12-well-plates with 1×104 
cells per well. The next day, medium was changed to serum-free DMEM. After 24 h, 2 × 
105 cpm (count per minute) [methyl-3H]thymidine were added to each well. At day 5, the 
medium was removed and each well was washed twice with cold PBS. The DNA in each 
well was precipitated with 5% cold trichloroacetic acid at for 2 h 4 °C, solubilized with 1% 
SDS solution for 2 h at 55 °C, followed by measurement of [methyl-3H]thymidine 
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3x104 PDL cells cultured on 10cm dishes were washed with phosphate-buffered 
saline, trypsinized, and fixed in cold 70% ethanol for 0.5 h. Ethanol was removed by 
centrifugation, and the pellets were resuspended in 1 ml of phosphate-buffered saline 
(PBS) containing 50 µg/ml propidium iodide and RNAse A (10 ug/ml) and incubated for 
30 min at 37 °C before FACS analysis. 
 
Cell Lysates and Immunoblotting 
Cells were lysed in RIPA buffer containing protease inhibitor cocktail 
(Sigma-Aldrich). SDS-PAGE gels were run and transferred to PVDF membranes 
(Bio-Rad, Richmond, CA). After blotting, the membranes were incubated overnight with 
primary antibodies and appropriate secondary antibodies (anti mouse IgG or anti rabbit 
IgG, Amersham, Buckinghamshire, UK) for 1 h. The membranes were washed and 
visualized by an ECL chemiluminescence detection kit (Amersham). Monoclonal 
antibody for LMP1 (1:1000) was from Abcam and monoclonal antibody for alpha-tubulin 
(1:1000) was from Sigma-Aldrich. 
 
RNAi 
For PDL cells or hBMSCs RNAi experiments, cells were seeded in 6-well-plates at 
2x105 cells per well, and transfected with 100 nM siRNA for 72 h in serum-free and 
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antibiotic-free DMEM. Next, media were changed and cells were stimulated with or 
without TGF-β1. siGENOME SMARTpool siRNA targeting Smad2, Smad4 and TAK1, 
and scramble control siRNA were purchased from Dharmacon.  
 
Quantitative RT-PCR 
Total RNA samples were extracted with RNAeasy Mini kit (Qiagen, Maryland) 
according to the manufacture’s instruction. 1 ug RNA was subjected to reverse 
transcription in a 50μl RT reaction using TaqMan Reverse transcription reagents (Applied 
Biosystems, Foster city, CA). cDNA was generated using random hexamer primers and 
oligo-T primers with 2:1 ratio). For quantitative real-time PCR, the generated cDNA was 
analyzed, in triplicate, with the Master Mix (Applied Biosystems) in the ABI7500 
Sequence Detection System. The results were normalized with 18s transcript. The 
primers and probes were ordered from Applied Biosystem. The probe sequences were: 
18S: Hs99999901_s1, TCCATTGGAGGGCAAGTCTGGTGCC; LMP1: 
Hs01103928_g1, CAAACCGCAGAAGGCCTCCGCCCCC.  
 
Determination of cell number by crystal violet staining 
3x103/cm2 PDL cells were seeded in 12-well plates in triplicate with osteogenic 
induction media. Media were changed every 3 days. Two weeks later, the cells were fixed 
with ice-cold methanol for 10 minutes. After PBS washing, 0.5% crystal violet solution 
was added for 10 minutes. Crystal violet was removed and the plates were washed 
carefully with water 5 times. Photographs were taken using a Nikon digital camera. For 
crystal violet quantification, Sorenson’s buffer (0.1 M sodium citrate, 50% ethanol, 50% 
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H2O) was used to extract the dye and further measured using a spectrometer (Beckman 
Coulter, Mason, MI) at A540. The optical density readout is positive correlated to cell 
numbers. 
 
In vitro mineralization assay 
PDL cells with stably expressed shRNAs were seeded in 6-well plates in triplicate at 
the density of 3x103/cm2. In order to induce PDL cells to mineralize, 50 ug/ml ascorbic 
acid, 5 mM beta-glycerol phosphate, and 10-8M dexamethasone were added to the 
medium for 2-3 weeks. Alkaline phosphatase (ALP) staining was performed as previous 
described [14]. Matrix mineralization was evaluated by Alizarin Red staining and Von 
Kossa staining.  
 
Statistical analysis 
All data are presented as the mean ± SD. The significance of the differences was 
determined by using the two-tailed Student's t-test and one-way ANOVA. In each figure, 







Figure 3-1 LMP1 is upregulated at early stage of osteogenesis in PDL cells. Primary 
PDL cells were induced for osteogenic differentiation. (A) RT-qPCR was used to evaluate 
LMP1 gene expression. A representative result of three independent experiments is shown. 
**, p<0.01; *, p<0.05 vs. non-induced control. (B) The LMP1 protein expression is 
shown by Western Blot. Relative expression ratios after normalization to GAPDH are 







Figure 3-2 LMP1 is required for PDL cell proliferation. Two double-stranded shRNAs 
targeting LMP1 and a scramble shRNA were designed and cloned into a retroviral system. 
After retrovirus infection and puromycin selection, all the survival cells were pooled. 
LMP1 expression was evaluated by RT-qPCR (A) and Western Blot (B). (C) LMP1 stably 
knocked down and control PDL cells were seeded in 6-well-plates at low density (3 x 
103/cm2). Osteogenic media were added to the cells, and media were changed every 3-4 
days. At day 3, 6, and 9, cells were harvested and counted by hemocytometry, n=6 per 
67 
 
group. (D) At day 10, cells were fixed and stained with crystal violet. (E) Subsequently, 
the crystal violet staining was washed and quantified. The optical density readout which 
correlates to cell numbers are shown. (F) LMP1 stably knocked down and control PDL 
cells were seeded in 12-well-plate at 3 x 103/cm2 and cultured in osteogenic induction 
media. 3H methyl thymidine was added after overnight attachment. At 5 d, the DNA was 
harvested and the 3H methyl thymidine incorporation was measured by scintillation 
counter. (n=4 per group). (G) PDL cells were cultured in 6-well-plates in serum free 
medium. 10% FBS was added, and RT-qPCR was used to examine the expression of 







Figure 3-3 LMP1 silencing decreases osteogenic differentiation in PDL cells. LMP1 
stably knocked down and control PDL cells were seeded in 12-well-plates at low density 
(3 x 103/cm2). Osteogenic medium was added to the cells, and media were changed every 
3-4 days. (A) At indicated time points, ALP activity was measured by ALP staining (left 
panel), and quantified assay (right panel). (B) Mineralization was assessed by Alizarin 
Red staining (left), and extracellular calcium concentration was quantified (right). (C) 
RT-qPCR was performed at d 7, 14, and 21 to evaluate the gene expression of several 
gene markers. a: p<0.01 compared to scramble shRNA in the same time point; b: p<0.05 







Figure 3-4 PDZ and ww-interacting domains are not sufficient to induce PDL cell 
proliferation. Full length LMP1 cDNA and a truncated form without any LIM domain 
were constructed into retroviral expression vector. PDL cells were transfected by 
retrovirus and selected by G418 for 10 days. Survived cells were pooled for the following 
experiments. Stable cell lines overexpressing LMP1 and LMP1-t were established in PDL 
cells from two different individuals. Representative data from 1 patient were shown here. 
(A) Truncated LMP1 only contains the first 144 aa including PDZ and ww interacting 
domains. (B) Endogenous and exogenous LMP1 proteins were detected by western blot. 
This antibody can detect the truncated form LMP1-t as well. (C) PDL cells were seeded 
in 6-well-plates at low density (3 x 103/cm2). Cells were harvested by trypsin and counted 
using hemocytometry, n=6 per group. (D) PDL cells were seeded in 6-well-plate at 3 x 
103/cm2 and 3H methyl thymidine was added. At 5 d, the DNA was harvested and the 3H 





Table 3-1: FACS analysis for cell cycle of PDL cells following LMP1 gene knockdown 
 G1 S G2/M 
Control shRNA 36.17 ± 1.41a,b 45.28 ± 1.37a,b 18.54 ± 0.75a,b 
shRNA 1 58.77 ± 1.16 30.07 ± 1.96 11.15 ± 0.89 
shRNA 2 44.24 ± 3.51 28.55 ± 1.80 27.02 ± 2.24 
PDL cells were cultured in 10 cm petri dishes in serum free medium overnight. 10% FBS 
was added for 24h. Cells were fixed and stained by PI, analyzing by FACS. n=4 per 




[1] Durick K, Wu RY, Gill GN, Taylor SS. Mitogenic signaling by Ret/ptc2 requires 
association with enigma via a LIM domain. J Biol Chem 1996;271: 12691-4. 
[2] Boden SD, Liu Y, Hair GA, Helms JA, Hu D, Racine M, Nanes MS, Titus L. LMP-1, 
a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology 
1998;139: 5125-34. 
[3] Boden SD, Titus L, Hair G, Liu Y, Viggeswarapu M, Nanes MS, Baranowski C. 
Lumbar spine fusion by local gene therapy with a cDNA encoding a novel osteoinductive 
protein (LMP-1). Spine 1998;23: 2486-92. 
[4] Liu Y, Hair GA, Boden SD, Viggeswarapu M, Titus L. Overexpressed LIM 
mineralization proteins do not require LIM domains to induce bone. J Bone Miner Res 
2002;17: 406-14. 
[5] Pola E, Gao W, Zhou Y, Pola R, Lattanzi W, Sfeir C, Gambotto A, Robbins PD. 
Efficient bone formation by gene transfer of human LIM mineralization protein-3. Gene 
Ther 2004;11: 683-93. 
[6] Minamide A, Boden SD, Viggeswarapu M, Hair GA, Oliver C, Titus L. Mechanism 
of bone formation with gene transfer of the cDNA encoding for the intracellular protein 
LMP-1. J Bone Joint Surg Am 2003;85-A: 1030-9. 
[7] Lattanzi W, Parrilla C, Fetoni A, Logroscino G, Straface G, Pecorini G, Stigliano E, 
Tampieri A, Bedini R, Pecci R, Michetti F, Gambotto A, Robbins PD, Pola E. Ex 
vivo-transduced autologous skin fibroblasts expressing human Lim mineralization 
protein-3 efficiently form new bone in animal models. Gene Ther 2008;15: 1330-43. 
[8] Strohbach CA, Rundle CH, Wergedal JE, Chen ST, Linkhart TA, Lau KH, Strong DD. 
LMP-1 retroviral gene therapy influences osteoblast differentiation and fracture repair: a 
preliminary study. Calcif Tissue Int 2008;83: 202-11. 
[9] Ott EB, Sakalis PA, Marques IJ, Bagowski CP. Characterization of the Enigma 
family in zebrafish. Dev Dyn 2007;236: 3144-54. 
[10] Seo BM, Miura M, Gronthos S, Bartold PM, Batouli S, Brahim J, Young M, Robey 
PG, Wang CY, Shi S. Investigation of multipotent postnatal stem cells from human 
periodontal ligament. Lancet 2004;364: 149-55. 
[11]Mao JJ, Giannobile WV, Helms JA, Hollister SJ, Krebsbach PH, Longaker MT, Shi S. 
Craniofacial tissue engineering by stem cells. J Dent Res 2006;85: 966-79. 
[12] Liu Y, Zheng Y, Ding G, Fang D, Zhang C, Bartold PM, Gronthos S, Shi S, Wang S. 
Periodontal ligament stem cell-mediated treatment for periodontitis in miniature swine. 
Stem Cells 2008;26: 1065-73. 
[13] Sonoyama W, Liu Y, Fang D, Yamaza T, Seo BM, Zhang C, Liu H, Gronthos S, 
Wang CY, Shi S, Wang S. Mesenchymal stem cell-mediated functional tooth regeneration 
in swine. PLoS One 2006;1: e79. 
[14] Riedl SJ, Salvesen GS. The apoptosome: signalling platform of cell death. Nat Rev 
Mol Cell Biol 2007;8: 405-13. 
[15] Durick K, Gill GN, Taylor SS. Shc and Enigma are both required for mitogenic 
72 
 
signaling by Ret/ptc2. Mol Cell Biol 1998;18: 2298-308. 
[16] Barres R, Gonzalez T, Le Marchand-Brustel Y, Tanti JF. The interaction between the 
adaptor protein APS and Enigma is involved in actin organisation. Exp Cell Res 
2005;308: 334-44. 
[17] Barres R, Gremeaux T, Gual P, Gonzalez T, Gugenheim J, Tran A, Le 
Marchand-Brustel Y, Tanti JF. Enigma interacts with adaptor protein with PH and SH2 
domains to control insulin-induced actin cytoskeleton remodeling and glucose transporter 
4 translocation. Mol Endocrinol 2006;20: 2864-75. 
[18] Yoon ST, Park JS, Kim KS, Li J, Attallah-Wasif ES, Hutton WC, Boden SD. ISSLS 
prize winner: LMP-1 upregulates intervertebral disc cell production of proteoglycans and 











THE POTENTIAL OF LMP GENE THERAPY IN PROMOTING 
MINERALIZATION IN VITRO AND IN VIVO    
  
4.1 Abstract 
      Gene transfer of key regulators of osteogenesis for mesenchymal stem cells (MSCs) 
represents a promising strategy to regenerate bone. The intracellular protein LMP1 (LIM 
domain mineralization protein) and a transcription variant LMP3 which is lack of any 
LIM domain are reported to induce osteogenesis both in vitro and in vivo. However, little 
is known about the effect of LMP gene therapy on periodontal ligament (PDL) cell 
osteogenic differentiation. This study sought to explore whether gene delivery of LMP1 
and LMP3 promotes PDL cell mineralization and bone formation. We found that stably 
overexpressed LMP1 in PDL cell by retroviral vector delayed mineralization. AdLMP3 
treatment, but not AdLMP1, induced significant matrix mineralization in PDL cells and 
hBMSCs. This effect was related to upregulated ALP and BSP gene expression. However, 
PDL cell transduced with AdLMP3 alone failed to induce ectopic bone formation in vivo. 
AdLMP1 and AdBMP7 combinatory gene therapy led to increased bone formation than 
AdBMP7 treatment alone. Future study will be needed to characterize inhibitory factors 




      Gene transfer of key regulators of osteogenesis for mesenchymal stem cells (MSCs) 
represents a promising strategy to regenerate bone. The intracellular protein LMP1 (LIM 
domain mineralization protein) belongs to the PDLIM protein family [1, 2]. At least three 
transcript variants of LMP exist in humans: LMP1, 2, and 3 [3]. LMP1 is the longest, 
encoding a 457 AA protein. LMP-2 has a 119-base deletion between +325 and +444 and 
a 17-base insertion at +444. The resulting derived protein contains 423 AA with the LIM 
domains intact. Human LMP-3 has the same 17 nucleotide insertion at +444, resulting in 
a shift in the reading frame that causes an early stop codon which encodes a 153 AA 
protein without LIM domains [3]. It has been reported that LMP1 and LMP3, but not 
LMP2 promote the osteogenesis program in MSCs. Overexpression of LMP1/3 in bone 
marrow stromal stem cells, calvarial osteoblasts, and dermal fibroblasts initiates 
osteolineage differentiation in vitro [2-5].  
  
      LMP gene delivery has been shown to promote bone formation in heterotopic 
(subcutaneous and intramuscular) and orthotopic (spineal fusion) sites. Intramuscular 
injection of AdLMP3 induced ectopic bone formation, which was shown by radiography 
and Von Kossa staining in tissue sections [5]. AdLMP3 transduced dermal fibroblasts 
formed ectopic bone in HA-collagen gel carriers. The same group also used AdLMP3 to 
repair critical size bone defects in rat mandibular ramus [6]. LMP1 gene delivery has 
been shown to induce new bone formation in a spine fusion model [7]. Bone marrow-
derived buffy-coat cells from rabbits were transduced by AdLMP1 adenovirus, and then 
the cells were implanted during posterolateral arthrodesis. The results showed that LMP1 
induces new bone formation and solid spine fusion [7].  
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      So far two theories have been proposed regarding the mechanism underlying the 
osteogenic effect of LMP1/3. First, LMP1/3 increases cell responsiveness to BMP 
signaling by preventing Smad degradation. Motifs directly interacting with the ww 
domain of SMURF1 were identified in LMP1 and LMP3. SMURF1 is a negative 
regulator in BMP signaling through mediating SMAD proteins degradation. The 
interaction between LMP1/3 and SMURF1 leads to SMAD1/5/8 accumulation in the 
cytoplasm, therefore the signaling effect induced by BMPs will be prolonged [8, 9]. 
Small peptides containing this motif can mimic the ability to block Smurf1 from binding 
to Smads in vitro. Second, LMP1/3 may be directly involved in the transcriptional 
regulation of osteogenesis. It was reported that BMP-2, BMP-4, BMP-6, BMP-7, and 
TGF-β1 expression was elevated in LMP1-overexpressing cells [10, 11].  
 
      Based on the potential of LMP in bone regeneration medicine, in this study, we 
hypothesized that LMP gene therapy will stimulate the osteogenic differentiation of 
periodontal ligament (PDL) cells, and promote in vivo bone formation. Using human 
PDL cells and bone marrow stromal cells (BMSC), we will compare the effect of LMP1 
and LMP3 in these two different mesenchymal progenitors.    
 
4.3 Results 
LMP1 overexpression in PDL cell fails to induce mineralization in vitro 
      We first tested whether LMP1 gene delivery promotes PDL cell osteogenic 
differentiation in vitro. We stably overexpressed LMP1 in human PDL cells by retroviral 
vector, and the exogenous LMP1 expression was confirmed by Western blot analysis 
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(Figure 4-1A). After that, PDL cells were transfected into osteogenic medium. Compared 
with vector control, less ALP staining positive cells were seen in LMP1-overexpressed 
PDL cells, and less mineralization was shown at the late stage (Figure 4-1B). We further 
tested whether LMP1 has direct effects on the late stage of mineralization by seeding 
PDL cells with very high cell density. High cell density resulted in rapid in vitro 
mineralization in control cells, however, little mineralization was seen in stable LMP1-
overexpressing PDL cells (Figure 4-1C). By using adenoviral vector, LMP1 was 
expressed in PDL cells as well. Similarly, we found that AdLMP1 had limited effect on 
promoting PDL cell mineralization compared to AdLacZ (Figure 4-1D). 
 
LMP3 stimulates strong mineralization in PDL in vitro 
       The effect of LMP3 on in vitro PDL cell osteogenic differentiation was also 
examined. Cells were transduced with a LMP3-expressing adenovirus (AdLMP3). As 
examined by Western blot analysis, AdLMP3 induced reasonable amount of protein 
expression at MOI 200 (Figure 4-2A). Increased MOI resulted in stronger ectopic protein 
expression, however, the toxic effect was stronger as well (data not shown). So MOI 200 
was the highest dose we used in our experiments. AdLMP3 gene transduction in PDL 
cells induced dramatic ALP expression at 1 week (Figure 4-2B). Compared with AdGFP 
control, the matrix mineralization also significantly increased after AdLMP3 treatment, 
which was shown by Von Kossa staining (Figure 4-2C). We also test the expression of 
some genes related to osteogenesis. Interestingly, we found that AdLMP3 treatment 
induce significant increase in ALP and BSP gene expression. However, Runx2, OCN, 
and Col1A1 were inhibited by both AdGPF and AdLMP3 adenovirus. Although 200 
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MOI is almost the minimal dosage for us to detect reasonable exogenous LMP3 protein 
in Western blot, considering the possible viral toxicity, we repeated the mineralization 
assay by using low MOI such as 50 and 100. At 100 MOI, AdLMP3 induced ALP 
activity and mineralization, but very limited effect was seen at 50 MOI (data not shown).    
 
LMP3, but not LMP1 stimulated matrix mineralization in BMSC in vitro 
      We also examined the effect of LMP1 and LMP3 gene delivery in the osteogenic 
differentiation of human BMSC. A specific population mesenchymal stem cell with 
strong osteogenic and angiogenic capabilities was tranduced by AdLMP1, AdLMP3 and 
control adenovirus. As shown in Fig 3A, MOI 200 induced reasonable expression of 
LMP1 and LMP3. Like the results with PDL cells, we found that expression of LMP3 
significantly upregulated matrix mineralization in vitro, compared with cells transduced 
with AdGFP and AdLacZ (Figure 4-3B, C). 
 
AdLMP1 and AdLMP3 gene delivery alone are not able to induce ectopic bone 
formation ex vivo 
      Because of the promising in vitro result regarding the effect of LMP3 in PDL cell and 
BMSC osteogenic differentiation, we further examined whether AdLMP3 can induce 
bone formation. PDL cells were transduced with AdLMP3, AdLMP1, and negative 
control adenovirus AdGFP. We also chose AdBMP7 and AdRunx2 as positive controls to 
mimic two possible mechanisms which LMP3 may use to stimulate bone formation. 
After adenovirus transfection, PDL cells were subcutaneously transplanted into 
immunocompromised mice. 4 weeks later, AdBMP7 and AdRunx2 treatment resulted in 
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solid ossicles, which were confirmed by X-ray (Figure 4-4A) and micro-CT (data not 
shown). Newly formed bone with bone marrow were clearly shown in von Kossa staining 
in samples that received AdBMP7 and AdRunx2 treatment (Figure 4-5B). This result 
suggested that PDL cells transduced with AdBMP7 and AdRunx2 were able to induce 
new bone formation in our model.  However, both AdLMP3 and AdLMP1 transduced 
PDL cells showed no sign of mineralization in vivo. Similar results were observed in low 
dose or high dose gene transduction, from MOI 50-200 (data not shown) . Similar results 
were also obtained at shorter (2 week) and longer time points (8 week) (data not shown). 
In order to rule out the possible effect related to different scaffolds, we tested both PLGA 
and type I collagen scaffolds. PDL cells and BMSCs transduced by AdLMP1 or 
AdLMP3 alone failed to promote ectopic bone formation in both scaffolds (Figure 4-4A, 
Figure 4-5A, C). Since the differentiation stage of the cell due to the carrier may be a 
critical issue, two different strategies were used in order to promote more mature PDL 
cells before transplantation: 1) PDL cells were transfected with AdLMP3 and then treated 
with osteogenic media for 7 days before transplation; 2) PDL cells were treated with 
osteogenic media for 7 days and then transfected with AdLMP3 before transplantation.. 
However, AdLMP3 gene delivery using either strategy failed to induce bone formation 
(data not shown). In summary, AdLMP3 alone does not appear to be able to induce 
ectopic bone formation by PDL cells in vivo.  
 
AdLMP1 and AdLM3 transduced BMSCs and ectopic bone formation 
      We also examined whether LMP gene delivery to BMSCs can stimulate ectopic bone 
formation. BMSCs were transfected with adenovirus expressing LMP1 or LMP3, then 
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cells were transplanted into immunocompromised mice by PLGA and collagen carriers. 
We found that AdLMP1 or AdLMP3 alone was not able to induce bone formation. 
However, BMSCs transfected by AdBMP7 stimulates significant bone formation.    
 
AdLMP1/3 and AdBMP7 combinatorial gene therapy showed limited effect to promote 
in vivo bone formation.  
      Since LMP1/3 may work cooperatively to amplify BMP signaling, we determined if 
it is possible that BMP expression is prerequisite for LMP gene therapy. Therefore, we 
co-tranduced PDL cells with AdBMP7 and AdLMP3, or AdBMP7 and AdLMP1. Using 
type I collagen scaffolds, BMSCs were subcutaneously implanted into 
immunocompromised animals. AdBMP7 induced minimal ectopic bone formation at low 
dose (MOI 50), whereas significant new bone formation were seen in high dose (MOI 
200) (data not shown). Combined with AdLMP1, low dose AdBMP7 induced more new 
bone formation than AdBMP7 alone, which was shown radiographically. Using 3-D µCT, 
we further confirmed the synergistic effect of LMP1 and BMP7. Cotransfection of 
AdLMP3 and AdBMP7 showed similar trends. We also tested whether cotransfection of 
the combinatory gene therapy in PDL cells can promote bone formation. Similar 
synergistic effects were observed between BMP7 and LMP1 although the data was not 
statistically significant due to our small sample number. (Figure 4-5).  
 
4.4 Discussion 
      Although it was reported that LMP1 can stimulate the ostegenic differentiation of rat 
primary calvarial osteoblasts and buffy coat cells [3, 7, 10], to our surprise, AdLMP1 was 
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not able to induce mineralization in vitro and in vivo in our hands, neither in PDL cells 
nor hBMSC. Similar findings were also seen in a retroviral gene delivery system, in 
which full length human LMP1 were stably expressed in PDL cells. Constitutive 
expression of LMP1 failed to induce the osteogenic differentiation of PDL cells as well. 
One possible explanation is that the LMP1 effect is very cell type specific. Another 
possibility is that LMP1 only works in a small dosage range and in a transient expression 
pattern. High dose, sustained LMP1 expression is inhibitory to osteogenic differentiation. 
This is supported by the fact that LMP1 only increases at the early stage of PDL cell 
differentiation, and rapid drops down to and even lower than basal level. In our gene 
expression pattern study, the expression level of LMP1 in mature mineralized tissue is far 
lower than PDL and gingival tissues. A more controllable “switchable” gene delivery 
system may be helpful to elucidate these possibilities.  
 
      In our study, we found that AdLMP3 is a positive regulator of in vitro matrix 
mineralization, both in human PDL cells and a specific population of human BMSC. 
Using retroviral a gene delivery strategy, we also showed that a truncated LMP1 without 
any LIM domains, which was highly similar to LMP3, demonstrated the capability to 
promote in vitro mineralization in PDL cells from curtain patients. This result was 
consistent with the observation by Pola et al. that AdLMP3 gene therapy induced 
osteogenic differentiation in dermal fibroblasts, embryonic fibroblasts (NIH3T3), and 
human BMSCs [5, 6]. We also found that AdLMP3 gene delivery significantly induced 
ALP and BSP gene expression in PDL cell. However, some other genes related to 
osteogenesis, such as Runx2 and OCN, didn’t show significantly increase because of the 
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possible toxic effect of adenovirus.  In order to further characterize whether the increased 
ALP expression was specifically related to LMP3, we measured ALP activity after 
adenovirus treatments at different dosages. Control viruses inhibited ALP activity at high 
dosages. However, AdLMP3 induced ALP activity with a positive correlated manner 
(data not shown).  
 
      In spite of its potent effect on mineralization in vitro, AdLMP3 failed to induce 
ectopic bone formation in vivo in our model. This result was inconsistent with the 
literature [5, 6]. Several possible explanations to our data set are listed here: 1) difference 
in cell delivery carrier. Other published work used Hydroxyapatite (HA)-collagen to 
deliver cells. However, we used either PLGA or collagen because these materials are 
transparent to x-rays. It is possible that osteoinductive HA is critical for the AdLMP3 
effect in vivo. 2) We used the subcutaneous implantation model because we considered 
this to be a logical model to evaluate ectopic bone formation [12-16]. However, the 
subcutaneous condition is very different from actual bone formation circumstance 
because of lack of related growth factors and extracellular signals. Although potent 
osteogenic factors such as AdBMP7 and AdRunx2 were able to induce new 
subcutaneously bone formation, less effective molecules may need more stringent 
conditions. Gene delivery in an in situ bone defect model may help clarify this issue. 3) 
Immunocompromised mice were used in our experiments because of the xeno-immune 
reaction between human cells and hosts. However this will compromise the AdLMP3 
effect on ectopic bone formation. In the literature, AdLMP3 was reported to successfully 
induced bone formation in autologous transplantations in immunocompetent animals. 4) 
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It is possible that the effect of AdLMP3 is cell type sensitive. PDL cell may not respond 
to AdLMP3 treatment in vivo.  
 
      AdBMP7 and AdLMP1 combinatory gene therapy resulted in more bone formation 
than AdBMP7 treatment alone. Thus far, it is not clear how LMP1 and BMP7 work 
together to promote bone formation. One possible mechanism is that LMP1 binds to 
Smurf1 and subsequently prevents Smad degradation. Thus, LMP1 prolongs the BMP 
signaling. If this is the case, it will be very important to identify the binding motifs which 
will be a potential pharmaceutical target for bone regeneration. Another possible 
mechanism is that LMP1 stimulates osteogenesis under high BMP7 levels. It would be 
important to identify the fate of the transplanted cells with LMP1 and BMP7 co-
transfection. 
       
      In summary, AdLMP3 gene delivery, but not AdLMP1, induced significant matrix 
mineralization in PDL cells and hBMSCs. This effect is related to upregulated ALP and 
BSP gene expression. However, PDL cell transduced with AdLMP3 alone couldn’t 
induce ectopic bone formation in vivo. We also found that AdLMP1 gene transfection 
promotes bone formation synergistically with AdBMP7. Future study will be needed to 
characterize the mechanisms underlying this synergistic effect.   
 




      The isolation of human periodontal ligament (PDL) cells and human bone marrow 
stromal cells (BMSC) was approved by the University of Michigan Health Sciences 
Institutional Review Board. PDL cells were obtained from extracted third molar or 
premolar teeth of healthy patients and cultured in 100 mm tissue culture dishes in a 
DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin [17]. PDL cells from 5 patients (Age range 20-50 years) were 
pooled together and were used at passages 2 to 6. Human BMSC cells were extracted 
from iliac crest and expanded in a bioreactor. MG63 osteosarcoma cells were maintained 
in DMEM with 10% FBS. 
 
Gene transduction 
      Full length cDNA of rat LMP1 was subcloned from osteosarcoma cell line ROS and 
inserted into an adenoviral vector. cGMP (current the Good Manufacturing Practice 
Regulations promulgated by the US Food and Drug Administration) grade adenoviral 
vectors for LMP1 was generated by University of Michigan Vector Core Laboratory 
(Ann Arbor, MI, USA). AdLMP3 and AdGFP were provided by Dr. Paul Robbins from 
the University of Pittsburgh. AdLMP1 was Ad-lacZ and AdBMP7 were purchased from 
the University of Michigan Vector Core Laboratory. AdRunx2 was kindly provided by 
Dr. Renny Franceshi. For in vitro transduction of cells, adenovirus was added to cells in 
serum-free medium. The next day, medium was removed and osteogenic medium was 
added with 10% FBS, 50 µg/ml ascorbic acid and 5 mM β-glycerol phosphate. 
 
LMP1 gene overexpression in PDL cells 
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Full length LMP1 gene was cloned from MG63 cells by RT-PCR, then was inserted 
into retrovirus vector pQC-XIN (Clotech, Mountain view, CA). After that, retrovirus 
production and transfection was performed following the similar protocol described in 
Chapter 3, and PDL cells were selected by G418 for 10 days.  
 
Quantitative RT-PCR 
Total RNA samples were extracted with RNAeasy Mini kit (Qiagen, Maryland) 
according to the manufacture’s instruction. 1 ug RNA was subjected to reverse 
transcription in a 50μl RT reaction using TaqMan Reverse transcription reagents (Applied 
Biosystems, Foster city, CA). cDNA was generated using random hexamer primers and 
oligo-T primers with 2:1 ratio). For quantitative real-time PCR, the generated cDNA was 
analyzed, in triplicate, with the Master Mix (Applied Biosystems) in the ABI7500 
Sequence Detection System. The results were normalized with 18s transcript. The 
primers and probes were ordered from Applied Biosystem.  
 
In vitro mineralization assay 
PDL cells with stably expressed shRNAs were seeded in 6-well plates in triplicate at 
the density of 3x103/cm2. In order to induce PDL cells to mineralize, 50 ug/ml ascorbic 
acid, 5 mM beta-glycerol phosphate, and 10-8M dexamethasone were added to the 
medium for 2-3 weeks. Matrix mineralization was evaluated by alizarin red staining and 
Alizarin Red staining.  
 
Cell Lysates and Immunoblotting 
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      Cells were lysed in RIPA buffer containing protease inhibitor cocktail (Sigma-
Aldrich). SDS-PAGE gels were run and transferred to PVDF membranes (Bio-Rad, 
Richmond, CA). After blotting, the membranes were incubated overnight with primary 
antibodies and appropriate secondary antibodies (anti mouse IgG or anti rabbit IgG, 
Amersham, Buckinghamshire, UK) for 1 h. The membranes were washed and visualized 
by an ECL chemiluminescence detection kit (Amersham). Monoclonal antibody for 
LMP1 (1:1000) was from Abcam and monoclonal antibody for alpha-tubulin (1:1000) 
was from Sigma-Aldrich. 
 
PLGA scaffold fabrication 
      We processed poly (dl-lactic-co-glycolic acid: 85:15) (PLGA) 3D scaffolds into 
porous foams by an established solvent-casting, particulate-leaching technique as 
previously described [18]. The resultant PLGA blocks were scaffolds containing 95% 
porosity and pore sizes in the range of 250–425 µm. These composites were cut into 
5x5x2 mm blocks, sterilized with UV light, and stored until use. 
 
Cell seeding in PLGA scaffold 
      Sterile PLGA blocks were incubated overnight in DMEM supplemented with 10% 
FBS, 100 units/mL penicillin–streptomycin, and 2 mM glutamine at 37°C. Before use, 
the medium in PLGA blocks was removed by autoclaved Whatman filter paper. Cells 
transduced with adenovirus were removed by trypsin, centrifuged at 1000 rpm for 5 
minutes, and resuspended in medium after the supernatant is aspirated. Subsequently, one 
million cells in 15 µL medium were dropped into PLGA scaffold blocks, cultured in 
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DMEM for 24 h in plastic dishes at 37°C. Then, PLGA blocks were implanted 
subcutaneously into the dorsa of immunodeficient (SCID). 
 
Cell seeding in type I collagen gel. 
BMSCs or PDL cells were trypsinized and harvested. Type I collagen (BD Biosciences) 
was neutralized and mixed with 1 million cells. 125 µl cell-gel mixture was added into 
96-well plate and placed in incubator for 1 h (370C, 5% CO2).  
 
Implantation of scaffolds in immunocompromised mice 
      All procedures were approved by the University of Michigan Committee of Use and 
Care of Animals. General anesthesia was administrated to NIH-III nude mice (5-8 week 
in age) by Isoflurane (Mallinckrodt Veterinary, Mundelein, IL, USA) for all surgical 
procedures. Two midsagittal incisions were made on the dorsa, and two subcutaneous 
pockets were created with forceps at both sides of each incision. Thus, each mouse 
allowed 4 blocks. The PLGA blocks or collagen gels containing different treated cells 
were inserted into the pockets and the incisions were closed with surgical staples. 
Implants were harvested 2, 4, or 8 weeks after surgeries.  
 
Radiography and histology  
      Radiographic analysis was performed utilizing a microradiography apparatus 
(Faxitron X-Ray Corp., IL, USA). For histology analysis, implants were removed from 
mice and fixed in 4% formaldehyde overnight. Samples were decalcified by 10% EDTA, 
subsequently were embedded in paraffin and sectioned at 5 µm. Hematoxylin and eosin 
87 
 
staining was used to determine tissue morphology. For von Kossa staining, undecalcified 






Figure 4-1 LMP1 gene transduction alone inhibits in vitro mineralization in PDL 
cells. Full length LMP1 cDNA were constructed into retroviral expression vector. PDL 
cells were transfected by retrovirus and selected by G418 for 10 days. Survived cells 
were pooled for the following experiments. (A) Exogenous LMP1 proteins were detected 
by western blot. (B) PDL cells were seeded at low density (3 x 103 cells/cm2). Cells were 
induced to osteogenic differentiation. ALP staining was performed at Day 10, and 
Alizarin Red stainings were shown at Day 21. (C) PDL cells were seeded in culture plates 
at high density (5x104 cells/cm2). Cells were induced to osteogenic differentiation. 
Alizarin Red stainings were shown at Day 14. (D) PDL cells were tranduced with 
AdLMP1 at different MOI, and the exogenous LMP1 expression was shown by Western 






Figure 4-2 LMP3 stimulates strong mineralization in PDL cells in vitro. (A) PDL 
cells were transduced with ALMP3 at different MOI. Western blot was used to test the 
LMP3 expression. (B) After AdLMP3 and AdGFP transduction, PDL cells were induced 
to osteogenic differentiation. At 1w, cells were fixed and ALP staining was performed. 
At 2w, von Kossa staining was used to assess the matrix moralization. (C) Real time PCR 
was used to test some gene markers related to osteogenesis. (*: p<0.05 compared to 







Figure 4-3 LMP3, but not LMP1 stimulated matrix mineralization in BMSC in vitro. 
(A) hBMSC cells were transduced with AdLMP1 and ALMP3 at different MOI. 
Westerblot was used to test the LMP1 and LMP3 expression. LMP1 is about 50 kDa, and 
LMP3 is about 16 kDa. (B) After AdLMP3 and AdGFP transduction, hBMSC cells were 
induced to osteogenic differentiation. At 2w, Alizarin Red staining was used to assess the 
matrix mineralization. (C) Extracellular calcium concentration was measured 2 weeks 
after adenovirus transduction. NT: no treatment. (**: p<0.01 compared to NT and 








Figure 4-4 Gene delivery of AdLMP3 alone failed to stimulate ectopic bone 
formation in vivo. (A) PDL cells were transduced with the indicated adenovirus (MOI 
100). 24 h after transduction, 1x106 cells were suspended into PLGA polymer scaffolds 
and implanted subcutaneously into immunodeficient mice as described under Materials 
and Methods. Implants were harvested and analyzed after 4 weeks. Typical 
microradiographic images from multiple repeating experiments are shown. (B) Von kossa 
stainings were performed. Mineralized areas in Von kossa-stained sections are black. 







Figure 4-5 AdLMP1 gene transduction promote bone formation synergistically with 
AdBMP7. BMSCs (A-B) and PDL cells (C-D) were co-tranduced by AdBMP7 (MOI 50) 
and AdLMP1 (MOI 200), or AdBMP7 (MOI 50) and AdLMP3 (MOI 200). 24 h after 
transduction, 1x106 cells were suspended into type I collagen scaffolds and implanted 
subcutaneously into immunodeficient mice. Implants were harvested and analyzed after 4 
weeks. (A) Typical microradiographic images from BMSCs experiments are shown. (B) 
Samples were scanned by µ-CT and quantitative analysis was performed to measure 
tissue mineral content in each samples. (n=4). (C) Typical microradiographic images 
from PDL cells are shown. (B) Samples were scanned by µ-CT and quantitative analysis 
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CHAPTER FIVE  
 
THE REGULATORY MECHANISM OF LMP1: A DOWNSTREAM GENE OF 
TGF-β1   
  
5.1 Abstract 
LMP1, also called LIM domain mineralization protein or Enigma, has been reported 
to improve the osteo-lineage differentiation in mesenchymal cells. Little is known 
regarding the regulation of LMP1 in human osteoblasts. This study sought to determine 
gene regulatory mechanisms of LMP1 at the molecular level. We show that LMP1 is a 
downstream target gene of TGF-β1 that is an early signal critical in preosteoblast 
proliferation and differentiation. TGF-β1 stimulates LMP1 expression in human PDL 
cells and other pre-osteoblasts, both at the mRNA level and protein level. However, 
neither BMP2 nor BMP6 could stimulate the LMP1 mRNA expression. We further 
demonstrated that LMP1 induction by TGF-β1 was specifically mediated by TGFβR 
because it was inhibited by the TGFβ type I receptor kinase inhibitor SB-431542. When 
SMAD4 and SMAD2 were knocked down by siRNA, there was no effect on LMP1 
expression levels when induced by TGFβ-1. We further identified that the activation of 
TAK1-JNK/p38 kinase cascade is involved in the LMP1 gene regulation by TGF-β1. 
TGF-β1 stimulates PDL cell proliferation, however, this effect is compromised when 
LMP1 is knocked down. We concluded that LMP1 is a downstream gene of TGF-β1, 
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involved in PDL cell proliferation. Our findings define a regulatory mechanism of LMP1 





LMP1 is a member of PDLIM protein family, which has conserved PDZ domain in 
the N-terminus and three LIM domains at the C terminus [1, 2]. LIM domains are 
cysteine-rich double zinc fingers, usually functioning in protein-protein interactions that 
are critical in different cellular processes, such as organ development, cytoskeletal 
organization and oncogenesis [3]. The PDZ domain of LMP1 binds to actin filaments [4, 
5]. Increasing evidence suggests that LMP1 functions as a scaffold protein, interacting 
with several proteins, such as protein kinase C [6], Ret/pct2 oncogene [1, 7], and InSR [1, 
7]. Recently, it has been shown that LMP1 is involved in the proliferation and 
differentiation of mesenchymal stem cells [2, 8-10]. It is reported that the expression of 
LMP1 was induced by glucocorticoid (GC) and BMP6, both of the mRNA and protein 
level [2]. However, the regulatory mechanism of LMP1 gene expression in mesenchymal 
stem cell is still largely unknown.  
 
TGF-β1 is one of the most abundantly deposited growth factors sequestered in bone 
matrix [11]. It has multiple functions in osteogenesis, regulating osteoblast precursor 
proliferation, differentiation and migration [11-14]. It is strongly expressed in 
proliferating osteoblasts during intramembranous ossification, and is strongly expressed 
in proliferating chondrocytes during chondrogenesis and endochondral ossification [15]. 
TGF-β1 knock-out mice display a 30% decrease in tibial length and a reduction in bone 
mineral content [16]. Recombinant TGF-β1 administration increases bone formation and 
promotes fracture healing in vivo[11]. TGF-β1 exerts cellular functions and affects gene 
expression through binding to two transmembrane serine/tyrosine kinase receptors (type I 
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and type II). When the type I receptor is activated, Smad dependent and Smad 
independent signaling pathways are utilized to mediate the extracellular stimulus to the 
nucleus. In Smad dependent signaling, Smad2 and Smad3 are phosphorylated by type I 
receptors, forming a trimeric complex with Smad4, subsequently translocating into the 
nucleus to activate target gene transcription [17, 18]. Besides the Smad dependent 
pathway, other signaling pathways are used by TGF-β1 including the Erk, JNK and p38 
MAPK kinase pathways. [17].  
 
This study sought to determine gene regulatory mechanisms of LMP1 in PDL cells 
and other mesenchymal progenitor cells such as bone marrow stromal cell. We also 
demonstrate that LMP1 is a downstream target gene of TGF-β1. Canonical Smad 
signaling pathway is not involved in the LMP1 gene regulation by TGF-β1. However, 
TGF-β1 regulates LMP1 through the activation of TAK1-JNK/p38 kinase cascade. 
Furthermore, LMP1 knockdown inhibits the proliferation effect mediated by TGF-β1. 




LMP1 gene and protein expression is regulated by TGF-β1.  
It is not clear how LMP1 gene expression is regulated in osteoblast progenitors. 
Based on its role in the early stage of PDL progenitor cell osteogenesis, we hypothesized 
that LMP1 may be regulated by early signals critical to proliferation and differentiation, 
such as TGF-β1, BMP2, BMP6, and PDGF-BB. To test our hypothesis, PDL cells were 
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treated with different growth factors and we first confirmed that all the growth factors can 
activate downstream signaling molecules, for instance, smad1/5/8 and smad2 (Figure 
5-1A). Subsequently, we found that TGF-β1 but not BMP-2/6/ stimulated LMP1 gene 
expression (Figure 5-1B). PDGF-BB also stimulated LMP1 expression, however, the 
effect is very limited compared to TGF-β1 (data not shown). Of the doses that we tested, 
2 ng/ml TGF-β1 induced consistent high level LMP1 gene expression (Figure 5-1C). We 
next examined the temporal profile of LMP1 in response to TGF-β1 in PDL cells. LMP1 
expression was induced by 6 h following TGF-β1 treatment, peaking at 24 h, and slowly 
returned to basal levels by 72 h (Figure 5-1D). Using Western blotting, we further found 
that LMP1 protein was increased at 24 post-treatment in PDL cells (Figure 5-1E). These 
results indicate that LMP1 is regulated by TGF-β1 in PDL cells. We further confirmed 
that TGF-β1-induced LMP1 expression occurs in other osteoblast progenitor cells as well, 
such as hBMSCs and MG63 cells, however, BMP2 and BMP6 had very little effect on 
regulating LMP1 gene expression (Figure 5-2A, 2C). Again, the TGF-β1 effect appears at 
around 6 hours after treatment, and peak at 24 hour (Figure 5-2B, 2D).  
 
TGF-β1 induction of LMP1 is specifically mediated by TGF-βI receptors.  
TGFβ signaling is initiated by ligand binding leading to the formation of receptor 
complexes, which comprises type II and type I serine/threonine kinase receptors. The 
type II receptor phosphorylates and activates the type I receptor which further 
phosphorylates various Smad molecules. Seven known type I receptors, also called 
activin receptor-like kinase (ALKs), have been divided into two categories: ALK-4, -5, 
and -7, corresponding to the TGFβ/Activin/Nodal branch through phosphorylating 
100 
 
Smad-2 and -3, while ALK-1, -2, -3, and -6 corresponds to the BMP/GDF branch and 
mediate Smad-1, -5, and -8 phosphorylation. SB-431542 is a selective inhibitor to ALK-4, 
5, and 7, without affecting ALK-1, -2, -3, and -6 and corresponding to BMP signaling. 
SB-431245 suppressed TGF-β1 induced LMP1 expression in PDL (Figure 5-3A). These 
results suggest that TGF-β1 induces LMP1 expression through TGF-βRI activation. In 
order to rule out the non-specific effect of SB-431245, we used siRNA to knockdown 
ALK5 expression in PDL cells. ALK5 knockdown partially blocked LMP1 expression 
stimulated by TGF-β1 (Fig. 3B). The partial inhibition may be explained by incomplete 
knockdown of ALK5 and the involvement of other receptor species such as ALK4 and 
ALK7. It has been reported that SaOS2 cells possess type I but no type II TGFβ receptors 
on the cell surface [19]. This led to the very limited effects by TGF-β1 on cell 
proliferation and proteoglycan synthesis of SaOS2 cells. We found that LMP1 is not 
induced by TGF-β1 in SaOS2 cells which further supports that the TGF-β1 effect on 
LMP1 expression is specifically through TGF-βI receptors (Figure 5-3C). 
 
TAK1-JNK/p38 cascade is involved in TGF-β1 induction of LMP1.  
To further identify the signaling pathway that TGF-β1 uses to stimulate LMP1 gene 
expression, we first knocked down the canonical Smad4 and Smad2 signaling by siRNA 
(Figure 5-4A, 4C). To our surprise, both Smad4 and Smad2 knockdown did not affect the 
up-regulation of LMP1 after TGF-β1 stimulation in PDL cells (Figure 5-4B, 4D). It is 
known that activated TGFβ receptors also trigger a Smad independent signaling pathways 
such as the mitogen-activated protein kinase (MAPK) signaling cascade [17, 20-22]. 
ERK, JNK and p38 are three members of MAPK signaling. U0126 is a MAP kinase 
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inhibitor selectively blocking the ERK1/2 phosphorylation but not JNK and p38. 
However, U0126 pretreatment failed to block TGF-β1-induced LMP1 gene expression 
(Figure 5-5A). Consistent with this result, another Ras-Erk signaling inhibitor PD98059 
had very limited effect on TGF-β1-induced LMP1 gene expression (data not shown). 
However, when we pre-treated PDL cells with SB203580 (p38 kinase inhibitor) and 
SP600125 (JNK kinase inhibitor), the LMP1 gene expression stimulated by TGF-β1 was 
significantly blocked (Figure 5-5B). To further confirm the roles of JNK and p38 in 
LMP1 gene expression, we used siRNA to knock down their upstream regulator TAK1 
(TGF-β-activated kinase 1). When TGF-βRI is activated, TAK1 phosphorylates JNK and 
p38, but not Erk1/2 [23]. After siRNA transfection, the expression of TAK1 was 
successfully knocked down ~90%. The gene knockdown of TAK1 inhibits the LMP1 
gene expression ~50% (Figure 5-5C). Taken together, non-canonical pathways, 
particularly TAK1-JNK/p38 cascade, play an important role in TGF-β1-induced LMP1 
upregulation. The phosphorylation of JNK and p38 kinase regulates downstream target 
genes indirectly through activating AP-1 or ATF2 transcription and translation. Using 
bioinformatics analysis, it was shown that there is an AP-1 binding site in the LMP1 
promoter, which suggested that TGF-β1 induction of LMP1 requires de novo protein 
synthesis [24]. To test this, we utilized Cycloheximide (CHX) to inhibit protein synthesis. 
Pre-treatment with CHX 1 h prior to addition of TGF-β1 effectively blocked LMP1 
mRNA induction in PDL cells (Figure 5-5D). This is consistent with the observation that 
LMP1 is not an early response gene of TGF-β1, and LMP1 mRNA begins to increase 
several hours after TGF-β1 treatment. Taken together, the activation of TAK1-JNK/p38 
kinase cascade is used by TGF-β1 to regulate LMP1 gene expression. 
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LMP1 knockdown attenuates the TGF-β1 effect on PDL cell proliferation.  
The effect of TGF-β1 on PDL cell proliferation appears to depend on TGF-β1 dose 
and cellular context. In the PDL cells we used, TGF-β1 stimulus significantly induced 
cell proliferation (Figure 5-6A). Next, we evaluated whether LMP1 is involved in the 
TGF-β1 effect on PDL cells proliferation. LMP1 knockdown of expression by shRNA in 
PDL cell resulted in a blockage of TGF-β1 dependent proliferation (Figure 5-6B). This 
further suggests that LMP1 may be involved in the proliferation effect of TGF-β1 in the 
early stage of PDL differentiation.   
 
5.4 Discussion 
To date, the regulatory mechanism of LMP1 remains “enigmatic”. Because of the 
upregulated expression of LMP1 in early stages of MSCs osteogenesis and the significant 
effect of LMP1 in PDL progenitor cell proliferation, we hypothesized that LMP1 is 
regulated by some of the mitogenic growth factors that provides early signals for 
osteogenesis. It is widely accepted that TGF-β1 stimulates MSCs proliferation during 
endochondral ossification and the early phase of bone fracture healing [11]. In this study, 
we identified that LMP1 is a downstream gene of TGF-β1 in human MSCs including 
PDL cells, bone marrow MSCs and the preosteoblast cell line, MG63. It is worth 
mentioning that TGF-β1 induces ~10 fold increase in LMP1 expression in MG63, and it 
would be interesting to further investigate its biological mechanisms. Although Boden et 
al. reported that LMP1 is regulated by BMP6 in rat calvarial osteoblasts [2], none of the 
BMPs that we tested can stimulate LMP1 expression in PDL cells and hBMSCs (data not 
shown). Though LMP1 may respond to different TGFβ superfamily members in different 
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species, our data strongly suggested that TGF-β1, but not BMPs, is the main regulator of 
LMP1 gene expression in human preosteoblastic cells. Besides TGF-β1, PDGF-BB is a 
mitogenic growth factor involved in periodontium development and regeneration [25-27]. 
The fact that LMP1 is regulated by TGF-β1 and PDGF-BB, but not other BMPs, also 
supports our hypothesis that LMP1 is a mitogenic player in PDL cells. 
 
Our studies demonstrate a signaling pathway in which TGF-β1 regulates LMP1 gene 
expression. It appears that canonical Smad signaling is not involved in TGF-β1-induced 
LMP1 expression. Instead, TAK1-JNK/p38 cascade mediates the TGF-β1 effect in PDL 
cells. Here, our data suggest a possible model of TGF-β1-induced LMP1 gene regulation 
(Figure 5-7). TGF-β1 ligand binding activates type II and I receptors, and then stimulates 
TAK1 activation which further phosphorylates JNK and p38 MAPK kinases. The 
phosphorylation of JNK and p38 kinase will activate LMP1 gene transcription through 
AP-1 or ATF2 activation. TGF-β1-induced LMP1 expression is independent of Ras-Erk 
signaling and Smad signaling pathways. Bioinformatics studies also support this model 
since there is an AP-1 binding site in the LMP1 promoter, whereas no Smad binding site 
is found [24]. In this model, TRAP6 may be the player mediating the type I TGF-β 
receptors and TAK1 because recently it has been shown that TRAP6 is specifically 
required for the Smad-independent activation of JNK and p38 via the physical interaction 
between its carboxyl TRAF homology domain with type I TGF-β receptors [28, 29]. Of 
note, other TGF-β1 downstream genes have been shown to be regulated by Smad 
independent, but JNK and/or p38 dependent, pathways. For example, TGF-β1 induces 
fibronectin synthesis through JNK dependent, but a Smad4 independent pathway [30]; 
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p38 signaling is used by TGF-β1 to induce connexin43 gene expression in normal murine 
mammary gland epithelial cells and these effects are Smad-independent [31]. Of course, 
it is still possible that other signaling pathways, such as RhoA and PP2A, are involved in 
the LMP1 gene regulation.  
 
In summary, we define a regulatory mechanism of LMP1 gene expression in PDL 
progenitor cells and other MSCs. This study will help better understanding the possible 
function LMP1 during PDL cell proliferation and differentiation.  
 
5.5 Materials and methods 
Cell culture 
The isolation of human periodontal ligament (PDL) cells and human bone marrow 
stroma cells (BMSC) was approved by the University of Michigan Health Sciences 
Institutional Review Board. PDL cells were obtained from extracted third molar or 
premolar teeth of healthy patients and cultured in 100 mm tissue culture dishes in a 
DMEM medium supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin/streptomycin [19]. PDL cells from 5 patients (Age range 20-50 years) were 
pooled together and were used at passages 2 to 6. Human BMSC cells were extracted 
from iliac crest and expanded in a bioreactor. MG63 osteosarcoma cells were maintained 
in DMEM with 10% FBS.  
 
Growth factor and kinase inhibitor treatment 
Confluent cultures of the above cells were brought to a stage of quiescence by 
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rinsing the monolayers with phosphate-buffered saline (PBS) and maintained in 
serum-free DMEM medium for 24 h prior to treatment. Recombinant human TGF-β1 was 
reconstituted and used according to the manufacturer’s directions (R&D, Minneapolis, 
MN)). For kinase inhibition experiments, different kinase inhibitors were suspended in 
DMSO and added to cells 1 h before TGF-β1 treatment. Cycloheximide and SB-431542 
were purchased from Sigma-Aldrich (St Louis, MO), while PD98059, SB203580, and 
SP600125 were acquired from A.G. Scientific Inc. (San Diego, CA). 
 
Short Hairpin RNAs (shRNA) and Retroviral Infection and Constructs 
Retrovirus-based shRNA knockdown system (pSIREN-RetroQ vector, from Clontech 
(Mountain view, CA) was utilized to stably knock down endogenous LMP1 expression. 
Target sequences were selected with software available on the Dharmacon web sites. 
Oligonucleotides synthesized by Invitrogen (Carlsbad, CA) were annealed and subcloned 
into retroviral vectors at EcoRI and BamHI sites. The two target sequences to LMP1 
identified were: si1: 5'-gtttgagtttgctgtgaagtt-3' and si2: 5'-gcaagagccgagataaagcca-3'. 
Non-target scramble shRNA sequence is: 5'-aaaaccgacggctatctct-3'. shRNA expression 
vectors were delivered into PDL cells using retroviral transduction according to the 
manufacturer’s directions. Briefly, PDL cells were transfected by retrovirus twice over 36 
hours, with a 12 hour interval between infections. Next, puromycin (1μg/ml) was added 
for 3 days. Resistant clones were pooled together for subsequent experiments. At least 6 
independent transfections had been performed and the efficiency and specificity of 




Cell Lysates and Immunoblotting 
Cells were lysed in RIPA buffer containing protease inhibitor cocktail 
(Sigma-Aldrich). SDS-PAGE gels were run and transferred to PVDF membranes 
(Bio-Rad, Richmond, CA). After blotting, the membranes were incubated overnight with 
primary antibodies and appropriate secondary antibodies (anti mouse IgG or anti rabbit 
IgG, Amersham, Buckinghamshire, UK) for 1 h. The membranes were washed and 
visualized by an ECL chemiluminescence detection kit (Amersham). Monoclonal 
antibody for LMP1 (1:1000) was from Abcam and monoclonal antibody for alpha-tubulin 
(1:1000) was from Sigma-Aldrich. 
 
RNAi 
For PDL cells or hBMSCs RNAi experiments, cells were seeded in 6-well-plates at 
2x105 cells per well, and transfected with 100 nM siRNA for 72 h in serum-free and 
antibiotic-free DMEM. Next, media were changed and cells were stimulated with or 
without TGF-β1. siGENOME SMARTpool siRNA targeting Smad2, Smad4 and TAK1 
ALK5, and scramble control siRNA were purchased from Dharmacon.  
 
Quantitative RT-PCR 
Total RNA samples were extracted with RNAeasy Mini kit (Qiagen, Maryland) 
according to the manufacture’s instruction. 1 ug RNA was subjected to reverse 
transcription in a 50μl RT reaction using TaqMan Reverse transcription reagents (Applied 
Biosystems, Foster city, CA). cDNA was generated using random hexamer primers and 
oligo-T primers with 2:1 ratio). For quantitative real-time PCR, the generated cDNA was 
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analyzed, in triplicate, with the Master Mix (Applied Biosystems) in the ABI7500 
Sequence Detection System. The results were normalized with 18s transcript. The 
primers and probes were ordered from Applied Biosystem. The probe sequences were: 
18S: Hs99999901_s1, TCCATTGGAGGGCAAGTCTGGTGCC; LMP1: 
Hs01103928_g1, CAAACCGCAGAAGGCCTCCGCCCCC; Smad4, Hs00232068_m1, 
GGCTTCCACAAGTCAGCCTGCCAGT; Smad2: Hs00183425_m1, 
TGGACACAGGCTCTCCAGCAGAACT. 
 
Determination of cell number by crystal violet staining 
3x103/cm2 PDL cells were seeded in 12-well plates in triplicate with osteogenic 
induction media. Media were changed every 3 days. Two weeks later, the cells were fixed 
with ice-cold methanol for 10 minutes. After PBS washing, 0.5% crystal violet solution 
was added for 10 minutes. Crystal violet was removed and the plates were washed 
carefully with water 5 times. Photographs were taken using a Nikon digital camera. For 
crystal violet quantification, Sorenson’s buffer (0.1 M sodium citrate, 50% ethanol, 50% 
H2O) was used to extract the dye and further measured using a spectrometer (Beckman 




All data are presented as the mean ± SD. The significance of the differences was 
determined by using the two-tailed Student's t-test and one-way ANOVA. In each figure, 







Figure 5-1 LMP1 gene and protein expression is regulated by TGF-β1 in PDL cells. 
(A) PDL cells were stimulated with TGF-β1 (2ng/ml), BMP2 (100ng/ml), or BMP6 
(100ng/ml). Phosphorylated-Smad1/5/8 and phosphorylated-Smad2 was examined by 
Western blot. (B) RNA was extracted after 24 h and RT-qPCR was used to evaluate 
LMP1 gene expression. LMP1 mRNA expression values was normalized to 18s RNA 
relative to that of serum-free controls. (C) After incubation in serum-free medium for 24 
hours, human PDL cells were stimulated with TGF-β1 (2 ng/ml, 10 ng/ml, and 20ng/ml). 
24 hours later, RNA was extracted and RT-qPCR was use to measure the expression level 
of LMP1. **: P<0.01 compared to serum free control; *: P<0.05 compared to serum free 
control. (D) PDL cells were treated by TGF-β1 at 2 ng/ml. At various time points, LMP1 
mRNA expression was measured by RT-qPCR. Open bar: PDL cells in serum free 
condition without TGF-β1. Closed bar: with TGF-β1. **: p<0.01 compared to serum-free 
control at the same time point. (E) PDL cells were treated with TGF-β1 for 24 hours. 







Figure 5-2 LMP1 gene expression is regulated by TGF-β1 in BMSCs and MG63 cells. 
Human BMSCs (A) and osteosarcoma cell line MG63 (C) were stimulated with TGF-β1 
(2ng/ml), BMP2 (100ng/ml), or BMP6 (100ng/ml). RNA was extracted after 24 h and 
RT-qPCR was used to evaluate LMP1 gene expression. hBMSCs (B) and MG63 cells 
(D)were treated by TGF-β1 at 2 ng/ml. At various time points, LMP1 mRNA expression 
was measured by RT-qPCR. Open bar: PDL cells in serum free condition without TGF-β1. 










Figure 5-3 TGF-β1 induction of LMP1 is specifically mediated by TGF-βI receptors. 
(A) Confluent PDL cells were free for serum for 24 h. Prior to adding TGF-β1 (2 ng/ml), 
PDL cells were pretreated by SB431542 for 1 h. 24 h after TGF-β1 treatment, LMP1 gene 
expression was measured by RT-qPCR, normalized to 18s mRNA, and given relative to 
that of serum-free control. Control: serum-free. SB(1): SB431532 in DMSO, 1μM. 
SB(10): SB431532 in DMSO, 10μM. n.s.: no significant difference. (B) ALK5 siRNA 
was transfected into PDL cells for 72 h in serum-free media, followed by TGF-β1 
stimulation. At 24 hours, RNA was extracted and qRT-PCR was used to examine the 
expression of ALK5 and LMP1. ALK5 knockdown compromised the effect of TGF-β1 on 
LMP1 gene expression. (C) Human steosarcoma cells (SaOS2) was stimulated with 








Figure 5-4 TGF-β1 induction of LMP1 was Smad4 and Smad2 independent. (A): 
PDL cells were transiently transfected with 100nM siRNA (targeting Smad4, Smad2, or 
non-targeting control) for 72 h, in serum-free and antibiotics-free DMEM. After treatment, 
media were changed (serum and antibiotics-free), and TGF-β1 was added. After 24 h, 
RT-qPCR was performed to measure gene expression. Smad4 and LMP1 mRNA 
expression were normalized to 18S mRNA. Left: The mRNA expression of Smad4 was 
examined by RT-qPCR. Right: LMP1 gene expression after Smad4 knockdown, w/wo 
TGF-β1 treatment. (C) Left: The mRNA expression of Smad2 was examined by 
RT-qPCR. Right: LMP1 gene expression after Smad2 knockdown, w/wo TGF-β1 
treatment. Results showed that Smad2 knockdown did affect TGF-β1-induced LMP1 
expression. siCtrl: scramble siRNA; siCtrl + T: scramble siRNA and TGF-β1 treatment; 
siSmad4: Smad4 siRNA; siSmad4 + T: Smad4 siRNA and TGF-β1 treatment; siSmad2: 







Figure 5-5 TAK1-JNK/p38 cascade is involved in TGF-β1 induction of LMP1. 
Confluent PDL cells were serum starved for 24 hours. Before adding TGF-β1 (2 ng/ml), 
PDL cells were pretreated by MAPK kinase inhibitors for 2 h. 24 h after TGF-β1 
treatment, LMP1 gene expression was measured by RT-qPCR. DMSO was used as the 
solvent for all the inhibitors. (A) The effect of Erk kinase inhibitor U0126 (10μM). (B) 
The effect of SB203580: p38 inhibitor, 25μM. SP600125: JNK inhibitor, 25μM. (C) PDL 
cells were transiently transfected with 100nM siRNA (targeting TAK1 or scramble 
control) for 72 h, in serum-free and antibiotics-free DMEM. After treatment, media were 
changed (serum and antibiotics-free), and TGF-β1 was added. After 24 h, RT-qPCR was 
performed to measure gene expression. Left panel: TAK1 gene expression. Right panel: 
LMP1 gene expression. siCtrl: scramble siRNA; siCtrl + T: scramble siRNA and TGF-β1 
treatment; siTAK1: TAK1 siRNA; siTAK1 + T: TAK1 siRNA and TGF-β1 treatment. (D) 
Confluent PDL cells were cultured in serum-free media for 24 h. Before adding TGF-β1 
(2 ng/ml), PDL cells were pretreated by cycloheximide (CHX) for 2 h. 24 h after TGF-β1 
treatment, LMP1 gene expression was measured by RT-qPCR, normalized to 18S mRNA, 
and given relative to that of serum free control. CHX(10): cycloheximide 10μM; 







Figure 5-6 LMP1 knockdown attenuates the TGF-β1 effect on PDL cells 
proliferation. (A) PDL cells were cultured in DMEM with low serum concentration (2% 
FBS), and some cells were treated by TGF-β1. At day 3 and day 6, cells were fixed and 
stained with crystal violet. The optical density readout which correlates to cell numbers 
are shown, n=3. *: p<0.05, **: p<0.01. (B) LMP1 knockdown PDL cells and control cells 
were cultured in 6-well-plates in 2% FBS, with/without TGF-β1. At day 3, 6, 9, cells 
were fixed and stained with crystal violet. The data showed the percentage change of 









Figure 5-7 Schematic overview of the regulation of LMP1 gene expression by 
TGF-β1. TGFβ-1 ligand binding activates type II and I receptors, and then stimulates 
TAK1-JNK/p38 cascade, therefore activates downstream gene transcription and 
translation, ultimately activates LMP1 gene expression. TGFβ-1-induced Enigma 
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SUMMARY AND FUTURE DIRECTIONS 
 
6.1 Summary of the thesis findings 
      There are four main aspects which have been addressed in this dissertation: 1) the 
gene expression profiles of LMP1 in periodontium under physiological, pathological, and 
regeneration circumstances; 2) the function of LMP1 in periodontal ligament cell (PDL) 
proliferation and differentiation;  3) the potential of AdLMP1 and AdLMP3 gene delivery 
in periodontal tissue regeneration; 4) the gene expression regulation mechanism of LMP1 
in periodontal ligament cell and other osteoblast precursors. 
       
      LMP1 is an intracellular scaffold protein that contains a PDZ domain and three LIM 
domains. LMP1 has multiple functions including regulating mesenchymal stem cell 
osteogenesis. Gene delivery of LMP1 and LMP3, a truncated form variant, was reported 
to induce bone formation in vivo in heterotopic and orthotopic sites. It is largely unknown 
about the expression profile, function, and regulation of LMP1 in the periodontal 
ligament cell, a multipotent cell which is able to differentiate to osteoblasts, adipocytes, 
chondrocytes, and neurons. The potential of LMP1/3 gene therapy for periodontal 
regeneration is still not clear. The main contribution of Chapter 2 was to identify the 
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gene expression pattern of LMP1 in normal, diseased, and regenerating periodontium. 
Using laser capture microdissection, I was able to detect mRNA expression from 
decalcified cranial and dental histological sections. I first identified that LMP1 was more 
highly expressed in periodontal ligament tissue and gingival tissue than mature alveolar 
bone, which suggested that LMP1 may be related to the homeostasis of the periodontium, 
in particular, the cell behavior of PDL cells. Next, I found that LMP1 was modestly 
increased in the extraction socket during the normal healing process, whereas, it was 
gradually decreased over time in the healing of bony defect around a dental titanium 
implant. These distinct expression patterns might be related to the different wound 
healing dynamics between tooth extraction repair and bone healing around titanium. 
More immune cells were seen to infiltrate to the osteotomy area in response to titanium. 
Very interestingly, I found that LMP1 gene expression was significantly up-regulated in 
the inflamed gingival tissue in experimental periodontitis. This information sheds some 
light on the roles of LMP1 in wound healing and host modulation to pathogenic infection.  
Another contribution of Chapter 2 was that, taking advantage of LCM, I generated the 
gene expression profiles of a panel of genes which may be related to periodontal wound 
healing and bone-implant osseointegration. These genes include growth factors, 
extracellular matrix protein, chemokines, and transcription factors. This data set will 
provide valuable information for the development of future periodontal regeneration 
therapies.  
 
      Most of the current research about LMP1 focused on its potential as a gene therapy 
agent for bone regeneration, hence very little is known about the physiological function 
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of LMP1. So far, LMP1 knockout mice still haven’t been developed, and LMP1 
knockdown in zebrafish is embryonical lethal. Therefore, gene knockdown experiments 
at the cell level are valuable for us to understand LMP1 function. Using PDL cells as a 
model, in Chapter 3, I stably knocked down LMP1 by shRNA and observed what basic 
cellular function was affected. I found stable gene knockdown of LMP1 impaired PDL 
cell proliferation, which further led to decreased mineralization in vitro. LMP1 
knockdown resulted in decreased DNA synthesis without significant cell apoptosis, and 
more cells were arrested in the G0/G1 phase. I also found that overexpression of LMP1 
increased cell proliferation. In the comparison of full length LMP1 and a truncated form 
which only contains PDZ and ww-interacting domains, we found that the PDZ and ww-
interactiong domains are not enough to mediate this effect. I concluded that LMP1 is 
involved in PDL cell proliferation. Our findings will contribute to the understanding of 
the physiological function of LMP1 in PDL cells and other osteoblast precursors. 
 
     In Chapter 4, I sought to explore whether adenoviral gene delivery of LMP1 and 
LMP3 can be used to enhance PDL cell mineralization in vitro and stimulate bone 
formation in vivo. Interestingly, we found that AdLMP3 treatment, but not AdLMP1, 
induced significant matrix mineralization in PDL cells and hBMSCs. The AdLMP3 effect 
might be related to the up-regulation of ALP and BSP gene expression. However, PDL 
cell transduced with AdLMP3 or AdLMP1 alone failed to induce ectopic bone formation 
in vivo. The same results were seen in BMSCs transduced with AdLMP3 or AdLMP1. 
Interestingly, when combined with AdBMP7, AdLMP1 treatment synergistically 
promoted ectopic bone formation in BMSCs. AdBMP7 and AdLMP1 combinatory gene 
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delivery tended to induce more bone formation, although the result is not statistically 
different due to our small sample size. Our studies are the first studies to investigate the 
potential of LMP gene therapy in periodontal regeneration. Although the results from 
single gene delivery experiment was unexpected, the striking in vitro effect suggests 
future study will be needed to characterize inhibitory factors preventing the osteogenic 
effect of LMP3 in PDL cells under in vivo circumstances, and optimize the gene delivery 
strategy. The synergistic effect between BMP7 and LMP1 is worthwhile to be 
investigated which will help to lower the BMP dose in bone regeneration. 
 
      The major contribution of the fourth portion of this dissertation was to determine the 
gene regulatory mechanisms of LMP1 at the molecular level. In Chapter 5, I show that 
LMP1 is a downstream target gene of TGF-β1 that is an early signal critical in 
preosteoblast proliferation and differentiation. TGF-β1 stimulates LMP1 expression in 
human PDL cells and other pre-osteoblasts, both at mRNA level and protein level. 
However, neither BMP2 nor BMP6 could stimulate the LMP1 mRNA expression. I 
further demonstrated that the activation of TAK1-JNK/p38 kinase cascade was involved 
in the LMP1 gene regulation by TGF-β1. TGF-β1 stimulated PDL cell proliferation. 
However, this effect was compromised when LMP1 is knocked down. Thus, the 
conclusion is the LMP1 is regulated by TGF-β1 through TAK1-JNK/p38 kinase axis. 
This study, for the first time, defined a regulatory mechanism of LMP1 in PDL cells and 
other mesenchymal stem cells.  
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      There is a great clinical need for periodontal regeneration. Gene delivery of LMP 
appears to be a candidate therapeutic for periodontal regeneration. The work described in 
this dissertation contributes to our understanding of the function and regulation of LMP 
in PDL cells, and will help us to better design future therapeutics to repair bony defects in 
the oral and craniofacial complex due to disease, trauma or congenital abnormalities.  
 
6.2 Future research directions 
      In this dissertation, we provided information about the regulation of LMP1 in 
periodontium under healthy and disease situation. Although the trends are very clear, 
some data showed relatively big variance. This is associated with our small sample size 
(n=4~6). It might be also related to  the accuracy of area of interest we selected in LCM 
since we identified the borders of the extraction socket and the osteotomy based on our 
experience.  Other methods such as bone labeling will help to identify the area of interest 
more precisely and easily.   
 
      Increasing evidence suggests that LMP1 may play an important role in joint/ligament 
homeostasis. A previous study reported that LMP1 is highly expressed in the future joint 
area in embryonic rats. Our data showed that LMP1 is highly expressed in PDL and 
gingival tissues, whereas at relative lower level in mature alveolar bone. When PDL cells 
were induced to osteogenic differentiation, LMP1 was upregulated at early stages and 
then decreases at the late stages. Furthermore, gene knockdown of LMP1 in PDL cells 
impaired its proliferation capability. Based on these findings, I propose that LMP1 is 
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important in periodontium homeostasis. A LMP1 knockout mouse model will be valuable 
to test this hypothesis in vivo. Since gene knockdown of LMP1 in zebrafish led to 
embryonic lethality, it is likely that LMP1 knockout mice will be embryonic lethal as 
well. Thus, inducible gene knockout or tissue specific gene knockout strategies can be 
considered in the future. Tet-on/Tet-off inducible gene knockout system will allow us to 
study the function of LMP1 in adult animals or in animals in certain development stages. 
LMP1 can be knocked out specifically in ligament tissues as well. In the past, several 
ligament/PDL specific markers have been identified, such as Scleraxis (Scx) and 
Periostin. Using the Scleraxis promoter or the Periostin promoter, LMP1 can be 
specifically knocked out in ligament tissue. The phenotype observed in these LMP1 gene 
knockout mice will be important to answer if LMP1 is important for ligament/periodontal 
ligament development and homeostasis.      
       
      In terms of the potential of LMP1 gene therapy, we found that gene delivery of LMP1 
alone is insufficient to promote ectopic bone formation. However, LMP1 seems to have 
synergistic effect with BMP7. In the future, more studies should be done to identify the 
mechanism underlying this effect. One possible mechanism is that LMP1 binds to 
Smurf1 and subsequently prevents the Smad degradation. Thus, LMP1 prolongs the BMP 
signaling. If this is the case, it will be very important to identify the binding motifs which 
will be a potential pharmaceutical target for bone regeneration. Another possible 
mechanism is that LMP1 stimulates osteogenesis under high BMP7 level. It would be 




      We have shown that AdLMP3 gene delivery promoted the matrix mineralization of 
PDL cells and BMSC in vitro. Although the in vivo results in ectopic bone formation 
model appeared to be elusive, in my opinion, it is still worthwhile to determine the 
mechanism behind these distinct differences. Some of the possibilities might be: 1) 
ectopic bone model is not an ideal approach to test the osteogenic potential of AdLMP3 
in vivo because other factors are needed for the successful AdLMP3 therapy are missing, 
such as growth factors, hormone, and extracellular matrix associated with bone formation. 
Previous successful experiences using AdLMP3 to induce bone formation mostly 
happened in or very close to bone defect area [1-3]. Therefore, in situ wound healing 
model in either a long bone or alveolar bone should be considered in the future.  2) The 
scaffold carrier in our tissue engineering model should be optimized. We used PLGA 
polymer in our study because it was easy to fabricate and handle for surgical procedure, 
and also because of its relative rigid physical property compared to gel foam. However, it 
may not be ideal for ectopic bone formation, especially for a molecules less potent that 
BMP and Runx2. Osteoconductive or osteoinductive materials, such as hydroxyapatite, 
may be considered in the future.     
 
      We also determined the gene regulatory mechanism of LMP1 in this dissertation. We 
found that LMP1 is regulated by TGF-β1 in PDL cell and other osteoblast precursors. 
This finding raised an interesting question: what are the roles of LMP1 to affect TGF-β1 
in MSCs. Although we have shown some preliminary data that LMP1 mediated the 
proliferation effect on PDL cells, other evidence also suggests that LMP1 may also be 
involved in the TGF-β1-induced cell migration. As we know, TGF-β1 is an important 
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chemoattactant for pre-osteoblasts. LMP1 has been reported to interact with several 
cytoskeleton related proteins, such as β-tropomyosin, tubulin, caldesmon, and meosin, 
and APS (Actin cytoskeleton organization) [4-7]. LMP1 can also bind to Smurf1, which 
plays critical effect on cell migration [7-10]. Taken together, it will be interesting to 
investigate if LMP1 is involved in TGF-β1-induced cell migration. It will be interesting 
as well to determine whether LMP1 has a role in the epithelial-mesenchymal transition 
(EMT). 
      
      This dissertation also demonstrated that LMP1 has multiple functions. Besides its 
roles in PDL cell proliferation and differentiation, increasing evidence suggest that LMP1 
may also play a role in the host immune response and bone resorption: 1) We showed that 
LMP1 is upregulated during the early stages of periodontal diseases; 2) LMP1 is highly 
expressed in leukocytes; 3) Recently, it was reported that LMP1 overexpression 
suppresses the activation of NF-κB in pre-osteoclasts. 4) Our data showed that LMP1 is 
regulated by TGF-β1, which is an important inhibitor of immune system. In the future, it 
will be valuable to identify the function of LMP1 in the host modulation of periodontal 
diseases. It would be interesting to investigate if LMP1 gene delivery can prevent 
periodontal bone loss.  
 
      In summary, studies in this dissertation demonstrate that LMP1 is an important 
regulator in PDL cell proliferation and differentiation. Gene delivery of LMP1 
synergistically promotes the osteogenic effect of BMP7. The studies also suggest that 
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LMP1 may play a role in the host modulation in periodontal diseases. These studies are 
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